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Venous neointimal hyperplasia (NH) leading to stenosis, thrombosis, and failure of 
hemodialysis arteriovenous grafts (AVG) is an important clinical problem that has no effective 
treatment for prevention. Many factors contribute to venous NH development; however, the 
underlying mechanisms are incompletely understood.  
The objectives are: i) to evaluate the effects of sunitinib on suppressing NH-promoting 
events in vivo, and on attenuating venous NH formation in an ex vivo perfused culture system; ii) 
to investigate the genomic responses underlying the pathophysiology of venous NH in a porcine 
AVG stenosis model; iii) to assess the genomic responses of porcine venous endothelial cells 
exposed to physiological or pathophysiological hemodynamic shear stress. 
In a porcine AVG model, elevated expression of platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), and their cognate receptors was seen at the venous 
anastomosis within 2 weeks after AVG placement. Sunitinib exhibited antiproliferative and 
antimigratory properties against vascular smooth muscle cells and endothelial cells (EC), which 
was supported by changes in the phosphorylation state or expression of the signaling proteins 
involved. Sunitinib also significantly attenuated the formation of venous NH in vein segments 
exposed to nonphysiological flow in an ex vivo culture model. 
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We investigated the genomic changes underlying the NH-prone and NH-resistant vein 
regions in a porcine AVG stenosis model to identify potential therapeutic targets to inhibit NH. 
Using microarray, gene expression changes in these two distinct regions were examined 5 and 14 
days following graft placement. In the NH-prone region, genes related to regulation of cell 
proliferation were most enriched among the significantly up-regulated genes at day 5, while 
up-regulated genes associated with osteo/chondrogenic vascular remodeling were most enriched 
at day 14. At both time periods, genes related to muscle phenotype were significantly 
down-regulated. 
Lastly, shear stress-responsive genes in porcine venous ECs exposed to physiologically 
low or pathologically high shear stress for a prolonged period were studied. We found that shear 
stress can induce a variety of cellular processes in ECs which may contribute to venous NH 
development. 
Our findings demonstrate the utility of an ex vivo perfused vein model to investigate 
NH-preventive pharmacotherapies, such as sunitinib. Our gene expression studies also provide 
insight into improved understanding of the molecular mechanisms that may be implicated in the 
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NEOINTIMAL HYPERPLASIA ASSOCIATED WITH HEMODIALYSIS  
ARTERIOVENOUS GRAFT STENOSIS 
 
1.1  Overview of Hemodialysis Vascular Access Modalities 
1.1.1 The three principal forms of hemodialysis vascular access 
As the prevalent end-stage renal disease (ESRD) population continues to show linear 
growth, the hemodialysis population also rapidly increases every year in the United States, with 
the number of patients requiring hemodialysis reaching nearly 384,000 at the end of 2010 (1). For 
these patients, hemodialysis is the major mode of renal replacement therapy before kidney 
transplantation is available. When initiating chronic hemodialysis, successful creation of a 
well-functioning vascular access is first required prior to treatment initiation. Currently, there are 
three principal forms of hemodialysis vascular access; the native arteriovenous fistula (AVF), the 
synthetic arteriovenous graft (AVG), and the central venous catheter (also called central venous 
line), each of which possesses its own merits and drawbacks as a vascular access. Selection and 
placement of an appropriate vascular access should be individualized and advance planning is 
essential because permanent vascular accesses can take weeks to months to establish. Vascular 
accesses are also prone to dysfunction and failure, leading to morbidity and hospitalization of 
hemodialysis patients. More than 20% of all hospitalizations in the hemodialysis population and up 
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to 50% of the first year hemodialysis costs are associated with vascular access complications (2).  
Central venous catheters, most often placed in the neck or chest, are primarily used as a 
temporary vascular access when the kidney disease is quickly progressed and the time to achieve 
a more permanent vascular access (i.e., AVG or AVF) is insufficient. In 2010 in the United States, 
over 80% of incident hemodialysis patients with no pre-ESRD nephrologist care initiated 
hemodialysis treatment with venous catheters alone as their vascular access, while 18% started 
treatment with catheters together with either maturing or functional AVF or AVG. Among patients 
who have had pre-ESRD nephrologist care for more than 12 months before hemodialysis initiation, 
the percentage of catheter use alone dropped to 41% and nearly 60% of patients had maturing or 
functional AVF or AVG (1). While venous catheters could be used long-term in some patients with 
difficult to develop functional AVF or AVG, they are highly prone to infection and other 
complications, such as narrowing of the veins in which they are placed, and therefore are not a 
suitable permanent vascular access for the majority of patients (3). 
Hemodialysis AVG and AVF are created by surgically connecting the artery and the vein, 
most frequently in the forearm, and the blood flows directly from the artery into the vein. Shunting 
of the arterial circulation thus provides adequate extracorporeal blood flow rates for effective 
dialysis, and once functional, these conduits can be used for long-term treatment. While AVG uses 
synthetic or biological materials as a graft, AVF provides direct connection between the native 
artery and the vein allowing the vein itself to mature into a thickened and dilated vessel suitable for 
repeated dialysis. Once established, AVF is universally recognized as the preferred choice of 
permanent vascular access because it has the least long-term complications and greatest 
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functional longevity, as compared to AVG or venous catheters (4). In order to maximize the use of 
AVF, National Kidney Foundation Dialysis Outcome Quality Initiative (DOQI) Clinical Practice 
Guidelines now strongly recommend that options for AVF placement be considered first in incident 
hemodialysis patients with adequate vascular anatomy, followed by prosthetic AVG if AVF 
placement is not possible (4). These guidelines also indicate that venous catheters should be 
avoided for hemodialysis and be used only if other vascular access options are not available (4). In 
accordance with these guidelines, the prevalence of AVG has steadily decreased in the United 
States in the last decade, while cases of AVF placement have increased significantly, with the 
national AVF placement rate exceeding 60% in prevalent hemodialysis patients as of April, 2012 (5, 
6). 
After creation, however, an AVF typically requires several months to mature into a 
sustainable vascular access, and a substantial proportion of AVF fail to properly develop within the 
expected time frame. Inadequate maturation, early thrombosis, and failure of first and subsequent 
cannulations all lead to unfunctional primary AVF failure (7). The primary failure rate of AVF 
reported in the current literature varies from 20% and up to 60%, depending on the study design 
and fistula patient population examined by each study (8-11). Early AVF failures may result in 
multiple attempts to construct a functional AVF, often leading to undesirable consequences such 
as exhaustion of vascular sites, patient intolerance, and the necessity of using a temporary venous 
catheter for a prolonged period. AVF are also subject to secondary failure in which failure occurs 
after the AVF has met dialysis suitability, and consequently, the conduit is permanently abandoned 
(12). Efforts to resolve such obstacles associated with AVF maturation and to improve AVF 
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functional longevity have been the subject of intensive research in recent years.  
1.1.2 AVG is still an important vascular access modality 
The alternative permanent vascular access modality to AVF is connecting the artery and 
the vein via a prosthetic AVG. Selection of a synthetic or biological graft material may take 
technical suitability, vascular surgeon’s experience, and cost into consideration (4). A fluorocarbon 
polymer polytetrafluoroethylene (PTFE) and its derivative, expanded PTFE (ePTFE), have been 
the prosthetic graft materials of choice, but other synthetic and biological materials such as 
polyurethane or bovine heterografts are also currently available with similar reported outcomes (4). 
Although AVG is now only preferably indicated for patients with failed AVF, for patients lacking 
suitable vessels to construct AVF, and for pediatric patients who have difficulty tolerating multiple 
venipuncture associated with AVF (13). However, AVG has several advantages over AVF in terms 
of reliably providing high blood flow rates and large surface area for cannulation, and the capacity 
to be used shortly after implantation (10). Hence, AVG is continuously being used in a significant 
number of hemodialysis patients. Unfortunately, the major drawback of AVG and the predominant 
reason for its acknowledged inferiority to AVF is that AVG is prone to developing stenosis, the 
abnormal narrowing of the blood vessel, followed by thrombosis and eventual occlusion of the 
conduit. This pathophysiology leads to the poor primary patency rate of AVG: approximately 50% 
and 25% at 1 and 2 years after placement, respectively (11, 14-16). AVG are also susceptible to 
technical failure that usually occurs within the first 30 days of placement, which are associated 
with inadequate graft configurations, poor surgical performance, and pre-existing patient 
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comorbidities (4).  
Nevertheless, currently AVG in hemodialysis patients is an indispensable access method, 
serving as one of the two available permanent vascular access modalities. Those unique merits of 
AVG over AVF have attracted researchers to study the mechanisms of AVG failure caused by 
stenosis and investigations into means of intervention to prevent stenosis. Currently, AVG stenosis 
and associated thrombosis are treated with routine radiologic and surgical procedures to restore 
graft patency. Angioplasty and stent placement are performed on stenosed and clotted grafts in 
conjunction with pharmacomechanical thrombolytic measures. When such interventions fail, 
surgical revision and thrombectomy of the graft is done to eliminate lesions before the placement 
of a new graft at a new anatomical location (17-19). Radiologic and surgical approaches, however, 
often cause injury to the native vessels, which predispose grafts to restenosis, and are inefficient 
in treating recurrent stenosis as new lesions can rapidly emerge over time (10, 17). Instead, 
attempts to pharmacologically prevent and/or treat AVG stenosis have become the most promising 
realm of investigation. Pharmacological approaches, however, require intensive and extensive 
research into the pathophysiology as thorough understanding of the underlying mechanisms 
resulting in AVG stenosis must precede selection of potentially effective therapeutic agent(s) to 
attenuate cellular and molecular events associated with the pathogenesis. In this chapter, the 
pathophysiology associated with the ePTFE grafts is reviewed specifically, although AVG stenosis 




1.2  Pathophysiology of AVG Stenosis 
1.2.1 Histological and biochemical properties of stenotic lesions 
The blood vessel wall consists of three distinct compartments: the (tunica) intima, the 
media, and the adventitia. AVG stenosis most frequently develops around the graft-venous 
anastomosis (hereafter referred to as the venous anastomosis) and adjacent vein regions, 
between the graft and the outflow vein, and less frequently at the graft-arterial anastomosis 
(arterial anastomosis). Aggressive neointimal hyperplasia (NH), defined as the abnormal growth 
and thickening of the neointima (inner-most layer of the blood vessel wall), is known as the most 
important cause of the majority of stenosis and thrombosis associated with AVG (10, 15, 16, 20, 
21). Roy-Chaudhury et al. demonstrated that histological and biochemical evaluation of human 
AVG stenotic tissues obtained from the venous anastomosis during an AVG surgical revision 
displayed hyperplastic lesions comprised of smooth muscle alpha-actin-staining cells, most likely 
smooth muscle cells (SMC) and/or myofibroblasts (adventitial fibroblasts that have transformed 
into an active contractile phenotype) derived from the media and/or the adventitia, and excessively 
deposited extracellular matrix (ECM) components (22). In addition, active macrophages and other 
cells of the immune system like T-cells were recruited to the synthetic graft material, and 
neo-microvascularization (angiogenesis) within the neointima and adventitia was observed (22). In 
these human specimens, various growth factors, including platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF), were also 
overly expressed (22), suggesting that such growth factor-mediated stimulation of cellular 
proliferation, migration and ECM protein accumulation may play pivotal roles in the formation of 
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the NH lesions. Various pathogenic factors that may contribute to the pathophysiology of AVG 
stenosis and NH development are discussed further in section 1.3. 
1.2.2 Large animal models to study AVG stenosis 
Due to the limitations of utilizing human specimens to study AVG stenosis pathophysiology, 
large animal AVG models (e.g., swine and canine) that can recapitulate the pathophysiology of 
AVG stenosis and subsequent graft failure in humans have been developed previously. In 
particular, swine have long been considered an excellent biomedical model to study a variety of 
human diseases due to their similarity in size, physiology, organ development, and disease 
progression to humans. In addition, the cardiovascular anatomy of swine is analogous to humans; 
therefore, swine have been used popularly in vascular research (23, 24). One of the first pig 
models of AVG stenosis described in the literature was by Rotmans et al., in which an ePTFE graft 
was placed between the common carotid artery and the internal jugular vein bilaterally in the neck 
of Landrace pigs (24). Kelly et al. also reported a similar pig AVG stenosis model in which the graft 
was placed between the femoral artery and the femoral vein (20). In these studies, the pig models 
rapidly developed thick NH lesions predominantly in the venous outflow tracts of AVG within a few 
weeks after the graft placement, and only minimal NH was observed at the arterial anastomoses. 
Consequently, the graft blood flow rate dramatically decreased in the patent grafts, eventually 
resulting in thrombotic AVG failure (20, 24). The histogenesis of porcine NH lesions was 
characterized by most of the key features described above by Roy-Chaudhury et al. in human 
AVG NH specimens, thus closely resembling the pathophysiology of human AVG stenosis (22). 
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These pig models of AVG stenosis and thrombosis have been widely adopted by us and others 
since then, especially for pharmacological and toxicological studies of potential antihyperplastic 
drugs and delivery of such drugs, although the detailed surgical methods to implant the graft may 
have varied from the original studies. In addition to pigs, dogs have also provided good 
experimental models for studying the pathophysiology of AVG stenosis. McLennan et al. and 
Masaki et al. reported the use of a canine AVG model in which the NH lesions formed at the 
arterial and venous anastomoses resembled the hyperplastic lesions in humans (25, 26). Despite 
the benefits of using whole animals, however, generation of a controlled pathologic environment 
and elucidation of its effects on NH development is often difficult to achieve in animal models due 
to the complexity of in vivo systems. Hence, such in vivo studies may be complemented by 
utilizing in vitro and ex vivo models described below in section 1.2.3. 
1.2.3 In vitro and ex vivo model systems to study AVG stenosis 
Because using animal models to study the pathophysiology of AVG stenosis and NH 
development are relatively costly and time-consuming, isolated in vitro cell cultures and ex vivo 
organ culture models of explanted blood vessels have been widely adopted. Monolayer and/or 
co-cultured vascular SMCs and endothelial cells (EC) have provided convenient tools to study the 
cellular characteristics under a controlled pathologic environment, as well as to rapidly assess 
responses to potentially effective therapies. Organ culture models are excellent experimental 
systems with a major advantage of using intact vessels, thus maintaining the native vessel wall 
architecture and intercellular and cell-matrix interactions (27, 28). Many studies have reported the 
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induction of neointima formation in explanted vein segments obtained from humans and from 
animals by applying a variety of controlled pathologic cues, such as high serum concentration, 
aberrant hemodynamics, or elevated oxygen tension under either static or perfused culture 
conditions (27, 29-34). The behavior of cultured vein segments in response to such stimuli closely 
mimics the hyperplasia development underlying vein graft stenosis in vivo in that highly 
proliferative smooth muscle cells and/or myofibroblasts directed towards the intima primarily 
constitute the hyperplastic lesions (31, 33). With our current knowledge, it is not clear how each 
pathologic stimulus induces a hyperplasia-prone state ex vivo, or whether the kinetics of NH 
development is similar to in vivo situations. In any case, ex vivo organ culture models serve as a 
valuable experimental system for investigation into the etiology and amelioration of NH associated 
with AVG stenosis.  
1.3  The Pathogenic Contributors of Venous NH Development 
1.3.1 Differential NH susceptibility between the arterial and the 
venous anastomoses 
Anatomically, NH predominantly forms in the susceptible “shoulder” and the “cushion” 
regions of the venous anastomosis in human specimens obtained from failed ePTFE AVG and in a 
porcine model of AVG stenosis (10). To date, the etiology of NH development selectively at the 
venous anastomosis is not clearly understood, although numerous studies postulate that multiple 
pathogenic factors specific to the venous anastomosis may contribute to the venous NH formation. 
During AVG placement surgeries, damage to the protective adventitia and endothelium in the 
10 
 
native vessels occurs. Normally, an intact endothelial layer lining the lumen produces nitric oxide 
(NO) and prostacyclins that inhibit aggregation and adhesion of platelets to the vessel wall (35). 
Injury to the adventitia can also be detrimental as damaged vasa vasorum in the adventitia can 
lead to tissue hypoxia and trigger downstream events leading to increased inflammation, cellular 
proliferation, and migration (36, 37). However, surgical trauma and subsequent wound healing 
activities upon graft placement are experienced by both the artery and the vein. In addition, local 
inflammatory responses caused by the presence of foreign graft material (bio-incompatibility) may 
be another common pathogenic feature in both vascular types (15, 20, 22).  
It is conceivable, however, that cells of the artery and the vein may possess inherent 
differences in terms of responding differentially to such pathogenic stimuli, contributing at least 
partially to the differential susceptibility to NH formation. In support of this, Li et al. demonstrated 
that arterial and venous SMCs display distinct proliferation profiles in response to each of the three 
PDGF isoforms, one of the key SMC mitogens abundantly expressed in NH lesions (38-40). This 
study also noted that the expression of certain PDGF receptors during quiescence was different 
between the arterial and venous SMCs. Li et al. also demonstrated the differential sensitivity of the 
arterial and venous SMCs to a PDGF receptor-inhibitor, imatinib, in that the venous SMCs were 
more sensitive to the drug’s effects (41).   
Moreover, the venous anastomosis harbors pathogenic factors less frequently observed at 
the arterial anastomosis. Upon graft placement, the arterial circulation is shunted into the venous 
system, abruptly exposing the vein to arterial-level high blood flow rates and blood pressure. 
Following this, the compliance mismatch between the stiff graft material and the native vein 
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causes the vein to stretch and dilate (10, 42, 43). This dramatic change in the vessel geometry 
generates a variety of mechanical stresses at the venous anastomosis: abnormally high and/or 
low fluid wall shear stress (WSS), increased circumferential wall stress, and disturbed and/or 
turbulent flow patterns (44-47). The correlation between such aberrant hemodynamic forces and 
venous remodeling has been reported in the literature. Gusic et al. showed that unphysiologically 
low WSS applied to explanted porcine vein segments induced hyperplasia formation in a perfused 
organ culture system (31). Thickening of the medial layer was observed when the explanted vein 
segments were exposed to elevated pressure beyond its normal physiological range (31). In a 
study by Budu-Grajdeanu et al., localized turbulent blood flow was suggested to stimulate the 
SMC production of growth factors known to promote NH formation in the context of venous NH 
(48). High WSS can also damage and denude the venous endothelium, exposing SMCs and the 
connective tissue to greater hemodynamic forces and circulating coagulation factors, leading to 
thrombosis and pathologic reactions (44, 45).    
The arterial anastomosis may also experience hemodynamic stresses as the inflow 
current appears to generate disturbed flow patterns at certain locations within the arterial 
anastomosis, but to a much lesser extent than the venous anastomosis (49). Unlike the veins, 
arteries by nature have much thicker elastic muscle structures and display quite different 
mechanical properties. Hence, the higher propensity of the venous anastomosis to develop NH is 
likely, at least in part, due to the greater hemodynamic and geometric changes seen at the venous 
anastomosis, compared to the arterial anastomosis. In an in vivo system like the porcine AVG 
stenosis model, examining the individual contributions of each pathogenic factor separately to NH 
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formation is difficult; therefore, a simpler model system is needed to characterize the key factors 
that render differential NH susceptibility between the arterial and venous anastomoses. 
1.3.2 Cellular and molecular mechanisms underlying NH formation 
Our current knowledge of the cellular and molecular mechanisms by which venous NH 
initiates and expands is far from complete. The NH lesions are highly cellularized with abnormally 
deposited ECM proteins and neo-microvessels that progress over time. Hence, pathogenic factors 
discussed in the above section 1.3.1 are thought to trigger a cascade of cellular and molecular 
events leading to the production and release of mediators that stimulate proliferation, migration, 
neo-microvascularization, inflammatory responses, and ECM remodeling. At the molecular level, 
the specific mechanisms provoking these events have not been investigated extensively, although 
a few studies have used genomic and proteomic approaches to provide an indication of the genes, 
proteins, and cellular signaling pathways uniquely modulated in NH lesions (50-52). In fact, NH 
can develop not only in the context of AVG stenosis but also in many arterial diseases (e.g., 
atherosclerosis, arterial balloon injury) and in other vein graft conduits, and the cellular 
compositions of arterial and venous NH do not appear to be significantly different from each other. 
The mechanisms of NH development have been more extensively studied in arterial NH; therefore, 
it is reasonable to review what is known from studies of arterial NH. A pathogenic cue, such as an 
injury, inflammation, and other forms of stress associated with arterial diseases, activates the 
adhering platelets and the vessel wall to secrete PDGF and other cytokines that stimulate arterial 
SMCs, ECs, and cells of the immune system. SMCs, in response, are stimulated to undergo 
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phenotypic transition from a quiescent contractile type to a synthetic (proliferative) type, likely 
involving gene expression changes that modulate the SMC phenotype (53, 54). PDGF also acts 
as a chemoattractant that promotes phenotypically modified SMCs to migrate into the intima (55). 
Activated SMCs, ECs, and immune cells recruited to the site of pathogenesis produce 
components of the ECM as well as enzymes that participate in ECM remodeling (53, 56, 57). 
These series of events are thought to promote the development of arterial NH lesion formation. It 
appears that venous NH development in vein grafts undergoes rather similar cellular processes to 
that of arterial NH, although initial pathogenic cues may be different from that of arterial diseases.  
1.3.3 Investigation of global events underlying NH development 
Identification of cellular pathways, or even more specifically, genes, their protein products, 
and other cellular components, that may be important in the early development of venous NH is 
expected to facilitate our understanding of the complex AVG stenosis etiology. Besides the 
well-accepted growth factor pathways activated by PDGF, VEGF, and other growth promoters, 
many studies have been conducted that hypothesized involvement of a variety of different 
pathways underlying NH formation. For instance, Sanders et al. showed that proinflammatory 
soluble epoxide hydrolases (sEH) are overly expressed in venous NH lesions in a porcine AVG 
model, and proposed a role for sEH in NH histogenesis (58). Jiang et al. suggested that monocyte 
chemoattractant protein-1 (MCP-1) and CC chemokine receptor 2 (CCR2) signaling in concert 
with certain physical stimulus plays a dominant role in vein graft NH development (59). It was also 
reported that hypoxia inducible factor-1HIF-1) may increase the expression of matrix 
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metalloproteinases (MMP) -2 and -9 and their tissue inhibitors in myofibroblasts, thereby leading 
to vein graft remodeling (60, 61). These studies emphasize the potential importance of specific 
pathways and their components, but a global view of cellular and molecular changes associated 
with the venous NH pathophysiology are lacking.  
In this respect, global transcription and proteomic profiling studies could provide a 
powerful means to explore all differentially regulated molecular events in NH. Misra et al. adopted 
a proteomic analysis with isotope-coded affinity tag (ICAT) to identify all differentially expressed 
proteins in stenotic tissues removed from a pig AVG model, and found that expression of 
-fetoprotein, fetuin-A, macrophage migration inhibitory factor (MIF), pyruvate dehydrogenase E1 
component, lactoferrin, and decorin were meaningfully modulated in NH lesions (51). Another 
study using the same techniques showed that a disintegrin and metalloproteinase 
thrombospondin-1 (ADAMTS-1) was significantly up-regulated in thrombosed human 
hemodialysis grafts (50). Currently, there are no published studies that have explored the global 
gene expression profiles of venous NH of AVG stenosis. However, high-throughput gene 
expression microarrays have been used to identify transcription profiles in arterial NH formation. 
For example, one study used gene expression microarrays and identified a set of genes 
associated with SMC and mesenchymal stromal cell proliferation and migration, inflammatory 
cytokines, ECM components, and muscle contraction to be significantly modulated in rat 
balloon-injured carotid artery neointima (62). Studies like these primarily provide preliminary data 
for potential biological targets and may require further investigation aimed at interfering with 
altered molecular events in NH.  
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1.4  Pharmacological Interventions to Prevent or Treat AVG Stenosis 
Efforts to attenuate NH development in arterial diseases and in vein grafts using a 
pharmacological approach have been an active area of research. Numerous broad spectrum 
antihyperplastic agents have been tested using in vitro and in in vivo vascular hyperplasia models. 
Strategies that have been examined for efficacy include use of small molecule drugs, antisense or 
decoy oligonucleotides, gene transfer, and cell-based therapies (10). Among these various 
strategies, our laboratory has focused on the use of small molecule therapies to attenuate AVG 
NH formation because these drugs have delivery and manufacturing advantages over biological 
reagents, and are less likely to cause immunologic reactions in vivo. Moreover, a variety of 
technologies to locally deliver these drugs to the site of action that circumvents any problems of 
systemic treatment can be applied, i.e., placement of a drug-eluting stent, direct coating of the 
graft with drugs, or implantation of a perivascular drug depot. For example, Lee et al. reported the 
use of paclitaxel-coated ePTFE grafts in pig AVG models and demonstrated that paclitaxel, a drug 
used to treat cancers, was effective in inhibiting NH formation and improving the AVG survival (63, 
64). The same drug was shown effective when used in a polymer-based sustained drug depot 
placed perivascularly at the anastomoses in a canine AVG model by Masaki et al. (26). Like 
paclitaxel that stabilizes mitotic microtubules and thus inhibits cell division, other small molecule 
drugs that have been explored previously act through mechanisms that suppress many of the 
cellular events occurring in NH lesions, such as cellular proliferation and migration, inflammation, 
angiogenesis, and thrombosis. Rapamycin (sirolimus) is an antiproliferative and anti-inflammatory 
agent clinically used to prevent rejection associated with organ transplantation (65). It has been 
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employed in coronary artery stents to prevent restenosis after angioplasty (66). Previously in our 
laboratory, we showed that administration of rapamycin-laden polymer gel was effective in 
reducing venous NH formation when evaluated in a porcine AVG model (67). Drugs with such 
mechanisms of action may indeed be promising therapeutic candidates; however, not all of the 
efforts have been successful. Dipyridamole is an antiplatelet agent that also inhibits SMC 
proliferation (68), and one clinical study suggested that daily dipyridamole administration with 
aspirin modestly decreased the incidence of PTFE graft occlusion in dialysis patients, although 
dipyridamole-mediated NH inhibition was not directly proved (69). However, a study by Kuji et al. 
found that local sustained delivery of dipyridamole in a porcine AVG model was ineffective in 
attenuating NH lesion formation (70). The in vivo efficacy of dipyridamole against AVG stenosis, as 
a consequence, remains to be further validated.  
Another class of drugs that may have potential as antihyperplastic agents is the receptor 
tyrosine kinase (RTK) inhibitors. These drugs potently counter the effects of various growth factor 
ligands at the receptor level, resulting in suppression of the downstream events, including cellular 
proliferation, migration, and angiogenesis. Targeting growth factor receptors in NH have been 
demonstrated previously by using specific antibodies against PDGF and bFGF receptors in arterial 
and AVF NH models (71, 72). Many of the RTK inhibitors were originally used in the treatment of 
malignant tumors, but their therapeutic potentials could encompass treatment of pathological 
lesions such as NH that closely resemble the pathophysiology of cancers. Li et al. studied the 
antiproliferative properties of imatinib, a small molecule RTK inhibitor developed as an 
antileukemic agent, in an in vitro vascular SMC culture system (41), and Makiyama et al. 
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demonstrated the antihyperplastic effects of imatinib in a rat NH model of balloon injury (73). To 
date, there are at least twelve clinically used RTK inhibitors, including monoclonal antibodies 
against RTK (74), many of which target more than one type of tyrosine kinase (74, 75). In Chapter 
2, we investigated a broad spectrum RTK inhibitor, sunitinib, which primarily targets all receptors 
of the PDGF and VEGF, for its potential as an antihyperplasia therapy (75, 76). In the clinic, 
sunitinib has been used to treat imatinib-resistant gastrointestinal cancers and renal stromal cell 
cancers. Its well-established antiproliferative and antiangiogenic properties in cancer cells might 
be utilized to attenuate hyperplasia development, including venous AVG NH (77-79).  
Inhibitors of sEH are experimental drugs that have gained recent attention as potential 
antihyperplastic agents. They have been shown in animal models to exhibit antihypertensive and 
antivascular remodeling effects in cardiovascular diseases (80, 81), and possess potent 
anti-inflammatory activities by potentiating the protective properties of epoxyeicosatrienoic acids 
(EETs) against inflammation. Sanders et al. demonstrated the intense expression of 
proinflammatory sEH in venous anastomosis tissues in a porcine AVG model, and suggested the 
possibility of sEH inhibitors as a novel therapeutic approach against AVG stenosis.  
Despite the availability of the above-listed pharmacological treatments with diverse 
mechanisms to potentially inhibit NH, currently there are no clinically effective therapies to prevent 
AVG stenosis. Yet it is not clear why such successful antihyperplastic drugs in model systems 
failed to exhibit efficacy in humans, but it is conceivable that our current understanding of the 
properties of those drugs tested as well as of the molecular mechanisms underlying NH 
development is incomplete. Moreover, inappropriate selection of in vitro or in vivo model systems 
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that may or may not properly mimic the clinical conditions of humans also cannot be ruled out. 
Future studies, therefore, may require advanced knowledge in these aspects in order to 
characterize and develop successful antihyperplasia therapies. 
1.5  Summary and Objectives 
Despite the technological advances, AVG vascular access dysfunction still remains an 
expensive, uncontrolled clinical problem for a large portion of the hemodialysis population. Our 
past and current efforts to better understand the complex pathophysiology associated with AVG 
stenosis have indeed led us to the improved knowledge of the mechanisms by which stenosis 
develops, thus enabling us to devise potential therapeutic strategies against the condition. Yet the 
problem is far from completely resolved and elucidation of the final solution awaits further 
laboratory and clinical studies.  
The objectives of this thesis work are: i) to evaluate the pharmacological effects of a RTK 
inhibitor, sunitinib, on suppressing NH-promoting events in vitro, and on attenuating venous NH 
formation in an ex vivo perfusion system; ii) to investigate the global genomic responses 
underlying the pathophysiology of venous NH formation in a pig AVG stenosis model; iii) to assess 
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PERFUSED VEIN CULTURE AS A MODEL SYSTEM TO TEST  





Neointimal hyperplasia (NH) is the predominant cause of stenosis in hemodialysis 
arteriovenous grafts (AVG) but currently, there are no clinically effective pharmacotherapies to 
prevent NH. We developed an ex vivo perfused vein model where NH develops in a clinically 
relevant flow environment, and examined the potential for this model to be used to test 
pharmacotherapies to prevent venous NH. Data from an in vivo porcine AVG stenosis model 
indicated that growth factors PDGF and VEGF, and their respective cognate receptors PDGFR- 
and VEGFR-2, were up-regulated at the graft-venous anastomosis within 2 weeks after AVG 
placement, with subsequent NH development by 4 weeks. Sunitinib, a broad-spectrum tyrosine 
kinase inhibitor, was therefore chosen to test in vitro. Sunitinib inhibited PDGF-stimulated 
proliferation of cultured smooth muscle cells (SMCs) and VEGF-stimulated endothelial cell 
proliferation in a dose-dependent manner. Migration of PDGF-stimulated SMCs was inhibited at 
similar concentrations of drug. Additionally, sunitinib inhibited PDGF-induced changes in 
phosphorylation of MAPK and PI3K/Akt signaling proteins and expression of cell-cycle regulatory 
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proteins of SMCs in vitro. Significant NH formation was observed in ex vivo cultures of porcine 
vein segments perfused for 12 days under nonphysiological venous wall shear stress, a key factor 
postulated to promote NH. Sunitinib (100 nM) inhibited NH formation under these conditions, with 
the intima-to-lumen area ratio decreasing from 0.45 ± 0.25 in the untreated vessels to 0.04 ± 0.02 
(p < 0.05). These findings demonstrate the utility of an ex vivo perfused vein model to investigate 
pharmacotherapies in a clinically relevant pathophysiological flow environment. 
2.2 Introduction 
Hemodialysis for patients with end-stage renal disease requires a vascular access that 
can provide high extracorporeal blood flow rates. A well-functioning native arteriovenous fistula 
(AVF) is the preferred form of vascular access because it has the least long-term complications. 
AVFs may, however, require months before becoming mature and usable, and up to 60% of 
native AVFs fail to mature (1, 7, 21, 31). Synthetic arteriovenous grafts (AVGs) made of expanded 
polytetrafluoroethylene (ePTFE) provide an alternative option. AVGs do not require maturation and 
can be used within days of creation. However, AVGs are associated with high stenosis rates, 
followed by thrombosis and occlusion, with 50% and 75% failure at 1 and 2 years after 
implantation, respectively (20, 37). Currently, AVG stenosis is treated by angioplasty, but the 
vascular wall injury associated with this procedure predisposes to restenosis (21). 
Neointimal hyperplasia (NH) accounts for practically all stenotic lesions in AVGs (14, 21). 
Histologically, NH consists of proliferating smooth muscle cells (SMCs) and myofibroblasts, mostly 
derived from the medial and the adventitial layers of the vessel wall (14, 18, 20, 23, 25, 29, 35). 
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While the compositions of arterial and venous NH lesions do not appear to be significantly different 
from each other, in most circumstances, progressive NH occurs at the graft-venous anastomosis 
(hereafter referred to as venous anastomosis) and less frequently at the graft-arterial anastomosis 
(arterial anastomosis) of AVG (2, 14, 21). It is thought that the venous anastomosis is more 
susceptible to multiple pathogenic factors that may potentiate NH formation, such as 
nonphysiological hemodynamics, damage to the protective adventitia and endothelium, and 
enhanced inflammation. In addition, the AVG shunts arterial blood flow directly into the vein, 
exposing the vein to high blood pressures and pulsatile and/or disturbed flow patterns, resulting in 
highly aberrant wall shear stress (WSS). The higher propensity of the venous anastomosis to 
develop NH is likely, at least in part, due to the greater hemodynamic changes seen at the venous 
anastomosis, compared to the arterial anastomosis.  
We have developed an ex vivo perfused organ culture model using explanted whole 
porcine vein segments. This ex vivo system enables us to recapitulate the pathological 
hemodynamic parameters occurring at the venous anastomosis in vivo, such as very low or high 
WSS, and can be utilized to efficiently identify agents that inhibit NH under these and other specific 
isolated conditions. In addition, whole vessel segments retain the vessel wall architecture as well 
as cell-cell and cell-extracellular matrix interactions that are more relevant than primary monolayer 
cell cultures to the in vivo environment. 
Currently, there are no drugs used routinely to prevent and/or treat NH, although the 
combination of aspirin and dipyridamole used prophylactically and sustained over a long period 
appears to produce a modest effect in retarding AVG failure (8). The early stage of NH 
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development requires the rapid growth and migration of cells. A rational approach to NH 
prevention would be the pharmacological inhibition of cell migration and proliferation (15, 20, 23). 
Potential molecular targets involved in NH formation were investigated in a porcine model of AVG 
stenosis, and early expression of the platelet-derived growth factor (PDGF) and vascular 
endothelial growth factor (VEGF) pathways were identified. Because the PDGF and VEGF 
pathways are both involved in NH, one candidate agent to prevent NH is the antineoplastic drug 
sunitinib, a multitarget receptor tyrosine kinase (RTK) inhibitor with well-established antiangiogenic 
and antiproliferative properties. The efficacy of sunitinib in inhibiting growth factor-stimulated 
proliferation of SMCs and endothelial cells (ECs), and the associated intracellular events, was 
examined in vitro and in the ex vivo perfused vein model. The results of the in vitro and ex vivo 
experiments demonstrate the utility of sunitinib as a pharmacological inhibitor of NH and the value 
of the ex vivo organ culture system for evaluating other potential NH-preventative agents.  
2.3 Materials and Methods 
2.3.1 Materials 
All cell and organ culture reagents were purchased from Cascade Biologics (Portland, OR) 
except for fetal calf serum (FCS), which was purchased from Atlanta Biologicals (Lawrenceville, 
GA). Sunitinib maleate was provided by Pfizer Inc. (New York, NY). Recombinant human 
platelet-derived growth factor-BB (PDGF-BB) and human vascular endothelial growth factor 165 
(VEGF165) were purchased from R&D Systems (Minneapolis, MN). Antibodies against PDGF-B 
chain, VEGF, PDGFR-, and VEGFR-2, were purchased from Thermo Scientific (Fremont, CA). 
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Antibodies against von Willebrand Factor (vWF) and Ki-67 were purchased from DAKO 
Pharmaceuticals (Carpinteria, CA). Anti-smooth muscle -actin antibody was purchased from 
Sigma (St. Louis, MO) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody 
was purchased from Abcam (Cambridge, MA). Secondary antibodies conjugated to horseradish 
peroxidase (HRP) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other 
antibodies were obtained from Cell Signaling Technologies (Danvers, MA). Precast 
polyacrylamide gels for electrophoresis, nitrocellulose membranes, and Immun-starTM HRP 
chemiluminescent kit were purchased from Bio-Rad Laboratories (Hercules, CA). Complete 
Mini-Protease Inhibitor Cocktail was obtained from Roche Applied Science (Indianapolis, IN). 
Bicinchoninic acid (BCA) protein assay kit was purchased from Pierce Chemical (Rockford, IL).   
2.3.2 Porcine model of AVG stenosis 
All animal procedures were performed in accordance with a protocol that was approved by 
the Institutional Animal Care and Use Committees (IACUCs) at the Veterans Affairs Salt Lake City 
Health Care System and the University of Utah. The porcine model of AVG stenosis has been 
well-established and employed routinely in our laboratory (16, 27, 33). Anesthetized female 
Yorkshire cross domestic pigs (Sigma Livestock, Salt Lake City, UT) weighing 30 to 35 kg were 
used for the implantation of a spiral-reinforced ePTFE graft (C. R. Bard, Murray Hill, NJ) 




Animals were sedated prior to surgery with a cocktail consisting of ketamine (4 mg/kg), 
telazol (4 mg/kg), and xylazine (4 mg/kg), and isoflurane inhalation was used for anesthesia during 
surgery. The graft (spiral-reinforced, 7 cm in length and 6 mm in internal diameter), cut at an angle 
of 55 at both ends, was attached to the CCA and EJV such that the graft loop lies in the cranial 
direction, creating both arterial and venous end-to-side anastomoses. Sodium heparin was 
administered intravenously during the surgery. Oral aspirin (Pharmaceutical Formulations, Edison, 
NJ), clopidogrel (Bristol-Myers Squibb, New York, NY) and enrofloxacin (Bayer, Pittsburgh PA) 
were administered peri-operatively. The animal was euthanized at the indicated time points. The 
AVG and adjoining blood vessels were retrieved en bloc for histology/immunohistochemistry (IHC) 
and morphometric studies as described below. A total of 23 pigs were used to study the time 
course of NH development, angiogenesis, and proliferation (see Figure 2.1 legend for the number 
of animals at each specific time point). 
2.3.3 Histology and morphometry in a porcine AVG model 
Grafted EJV segments (1-2 cm in length) at the vein-graft junction were harvested at 
various time points after the AVG implantation. Explanted EJV segments were perfusion-fixed in 
10% neutral-buffered formalin to maintain the in vivo geometry and then immersed in formalin for 
24 to 48 h. Paraffin-embedded 5 m thick tissue cross-sections from the center of the venous 
anastomosis, where the ePTFE graft and the vein wall comprise approximately the same 
proportion in the tissue section (20), were stained with elastic Van Gieson’s stain (Accustain Elastic 
Stain, Sigma), examined under light microscopy, and digitally photographed using the QImaging 
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system (Surrey, BC, Canada). The external and the internal elastic laminae were visualized. The 
surface areas of the NH (defined as the tissue area between the venous lumen and the internal 
elastic lamina), the media and the graft were quantified separately using ImageJ 1.45 software 
(http://rsb.info.nih.gov/ij/). The NH index was calculated as the ratio of the NH surface area to the 
combined surface area of the graft and media, which corrects for variations in the angle of the 
histological sections and thus, the apparent thickness of the vascular wall layers.  
Tissue sections from the same anastomotic region were immunostained for the 
endothelial marker, vWF, to identify ECs. Neovascularization was fairly homogenous within each 
region. Direct microscopic manual counting of the neovessel densities in the NH and the adventitia 
in a given image field was performed separately by three independent observers at a 
magnification of x 20. The final counts included small lumens surrounded by vWF-positive cells 
and single or clusters of vWF-positive cells. We selected the most vascularized areas at a low 
magnification (x 5) and counted the representative areas at a higher magnification (x 20).  
Tissue sections from the same anastomotic region were also immunostained for the 
nuclear proliferation marker, Ki-67, present in the neointima and the adventitia separately. The 
number of Ki-67-positive nuclei and the number of total nuclei stained with hematoxylin in a given 
image field were counted by three independent observers at a magnification of x 20. The 
proliferation index (PI) was calculated as the number of Ki-67-positive nuclei divided by the total 
number of nuclei x 100.  
To determine the expression of VEGF, VEGFR-2, PDGF-B, PDGFR- in the NH lesions, 




2.3.4 Cell culture 
Primary human aortic smooth muscle cells (HASMC), human saphenous vein smooth 
muscle cells (HVSMC), and human umbilical vein endothelial cells (HUVEC) were obtained from 
Cambrex (Chicago, IL). SMCs were identified by positive staining with anti-smooth muscle -actin. 
The endothelial phenotype of HUVECs was confirmed by positive anti-factor VIII staining. Cells 
were maintained in their respective basal media supplemented with 10% or 2% FCS, respectively, 
additional growth factors, and antibiotics (gentamicin/amphotericin B) in a humidified 37 C 
incubator with 5% CO2 and 95% ambient air. Fresh culture media was supplied every 2 to 3 days. 
For all experiments, both HASMCs and HVSMCs from three different donors and cells at passage 
3 to 7 were used. SMCs were cultured to approximately 70 to 80% confluence and HUVECs to 90% 
confluence, and then rendered quiescent before each experiment as described below.   
2.3.5 In vitro proliferation and migration assays 
For proliferation assays, SMCs and HUVECs were seeded on 96-well microtiter plates at 
a density of 5x103 cells/well and cultured to the desired confluence. Before each experiment, cells 
were rendered quiescent by incubating for 24 h with their respective basal media containing 0.5% 
FCS but no additional growth factors. These cells were then pretreated with various 
concentrations of sunitinib (1 to 1,000 nM) for 1 h, followed by stimulation with either PDGF-BB (50 
ng/ml) or VEGF165 (50 ng/ml) for SMCs and ECs, respectively. After 48 h, DNA synthesis was 
assessed by 5-bromo-2’-deoxyuridine (BrdU) incorporation (Cell Proliferation ELISA, Roche 
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Applied Science). In brief, BrdU labeling solution was added to the culture medium for 12 to 24 h 
before the cells were fixed for 30 min. Cells were then incubated for 90 min with 
peroxidase-conjugated anti-BrdU antibody. BrdU-antibody complexes were detected by a 
colorimetric reaction with the substrate (3,3',5,5'-tetramethylbenzidine), and the optical density 
read at 450 nm in a microplate reader (Multiskan Ascent, Thermo Electron Corporation, San Jose, 
CA). At least six replicate experiments were analyzed for each sunitinib concentration for both 
SMCs and ECs.  
SMC migration was assessed using the InnoCyteTM Cell Migration Assay (Calbiochem, 
San Diego, CA) according to the manufacturer’s instructions. In brief, a suspension of 5x104 
HASMC was loaded into the well of the upper migration chamber (the insert) which contained 
media with 0.5% FCS but no additional growth factors. The upper migration chamber was then 
attached to the lower chamber (the tray). Cells were preincubated with various concentrations of 
sunitinib added to the media in both the upper and lower chambers for 1 h, and then 50 ng/ml of 
PDGF-BB was added to the lower chamber. Cells were allowed to migrate through the porous 
membrane towards the lower chamber for 4 h in a humidified 37 C tissue culture incubator. Finally, 
the migrated cells attached at the underneath side of the membrane were dislodged and 
fluorescence-labeled with Calcein-AM, followed by quantification at 485 nm using a standard 
fluorescence microplate reader (SpectraMax 250, Molecular Devices, Sunnyvale, CA). At least 3 





2.3.6 Western blotting 
Signal transduction pathways activated by PDGF-BB in HASMCs were explored by 
examining the phosphorylation of ERK1/2, Akt, p70S6K, and rpS6 using Western blotting. 
Expression of cell-cycle regulatory proteins cyclin D1, p21, and p27 was also assessed. Quiescent 
HASMCs were exposed to various concentrations of sunitinib for 1 h, then stimulated with 50 
ng/ml of PDGF-BB for 10 min (to determine early changes in protein phosphorylation) and for 24 h 
(to assess changes in cell-cycle regulatory protein expression). Cells were then washed twice with 
ice-cold phosphate-buffered saline (PBS) and lysed with lysis buffer (PBS containing 0.6 percent 
NP-40, 150 mM NaCl, 10 mM HEPES, pH 7.9 with protease inhibitors). Protein concentrations 
were determined by the BCA protein assay. Cell lysates containing equal amounts of total protein 
were subjected to SDS-PAGE on precast 4 to 20% gradient polyacrylamide gels (Life 
Technologies, Grand Island, NY). Following electrophoresis and transfer to nitrocellulose 
membranes, immunoblots were incubated overnight at 4 C with primary antibodies specific for the 
respective proteins or for the phosphorylated form of the proteins. Immunoblots were incubated 
overnight with primary antibodies specific for the respective proteins or for the phosphorylated 
form of the proteins. Immunoblot detection was performed using an Immun-starTM HRP 
Chemiluminescent kit according to the manufacturer’s instructions.  
2.3.7 Ex vivo perfused vein culture and analysis 
Porcine internal jugular vein (IJV) segments were harvested with sterile techniques from 
female Yorkshire cross domestic pigs weighing at least 30 kg that have been used for AVG model 
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experiments. In most of the AVG pig studies conducted in our laboratory, only CCA and EJV 
segments were manipulated and experimentally utilized and IJV typically remains intact. IJV 
segments harvested this way do not exhibit pre-existing NH lesions and are not expected to be 
different from IJV collected from unoperated animals.  
The ex vivo perfusion system is similar to that described by Gusic et al. (5, 11, 12), with 
modifications regarding the vessel chamber and the long-term application of laminar flow with 
various WSS values. Briefly, explanted IJV segments were fixed at their in vivo length (3 to 5 cm) 
onto stainless steel tubes using surgical sutures, and bathed in a vessel chamber filled with 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 30% FCS and antibiotics but no 
additional growth factors. Vein segments were perfused with the same oxygenated media that was 
recirculated at a laminar, constant volumetric flow rate to generate specific calculated WSS values 
inside the vessel. Volumetric flow rate was measured manually through a flow valve positioned 
immediately downstream of the vessel chamber. Vein segments were cultured for 12 consecutive 
days with media flowing continuously (N = 6). Fresh media was supplied every 2 to 3 days. Sterile 
conditions were maintained in the entire system in the 37 C constant-temperature hood. In 
sunitinib-treated veins (N = 3), sunitinib was added to the circulating media as well as to the media 
that filled the vessel chamber on the second day of ex vivo culture in order to allow vessels to 
recover from explantation procedures, and was added to the fresh replacement media to maintain 
a constant final drug concentration of 100 nM throughout the entire experiment. 
WSS () was calculated using the following equation:  = (4Q)/(r3), where  is the 
viscosity of the culture media containing serum ( = 0.01 Poise), Q is the volumetric flow rate 
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through the vessel adjusted to generate the desired WSS, and r is the inner radius of the vessel 
lumen measured at the time of harvest. The WSS inside the vessels was maintained at <1 
dyne/cm2 at the beginning of culture (N = 5), a value that is considered nonphysiologically low for 
the normal vein. Veins are typically exposed to 1 to 5 dyne/cm2 under normal conditions. One of 
the untreated control IJV segments had a small inner radius such that we were unable to generate 
an initial low WSS value; therefore, this vein segment was subjected to a WSS of >50 dyne/cm2 
which is also nonphysiological for the vein. Because we observed the greatest NH formation in this 
particular vein segment among all other segments tested, this particular piece of data was 
included in our study. A total of five animals were used to collect veins for the perfusion 
experiments. 
Explanted IJV segments exposed to the above-described WSS conditions were fixed in 10% 
neutral buffered formalin at the end of each perfusion experiment. After formalin was directly 
perfused into the lumen of the vessel through the metal tubes, the entire vessel was immersed in 
formalin for 24 to 48 h. Paraffin-embedded cross-sections were stained with either 
hematoxylin/eosin (Poly Scientific, Bay Shore, NY) or Van Gieson’s stain. The cross-sectional 
surface areas of vessel wall regions were determined using planimetry under light microscopy and 
the Q-Imaging system, and were quantified using ImageJ software. The results were used to 
calculate the intima-to-media area ratio (I/M) and the intima-to-lumen area ratio (I/L). In IHC, 
SMCs and/or myofibroblasts were identified by positive staining with anti-smooth muscle -actin, 
while proliferating cells were identified by positive staining with anti-Ki-67. ECs were identified by 




Some IJV segments were kept in a static condition for 14 days. After harvest, vein 
segments of about 1 to 2 cm were cut longitudinally to expose the lumen and pinned up on a 
sterile mesh, and cultured with DMEM containing 30% FCS in a tissue culture dish. 
Formalin-fixation, paraffin-embedding, and Van Gieson’s stain was performed as described above. 
2.3.8 Data analysis 
Results are reported as means ± standard deviation (SD). Two-tailed Student’s t-test and 
one-way analysis of variance (ANOVA) with Tukey’s post test were performed using GraphPad 
Prism version 5.00 for Windows (GraphPad Software, San Diego, CA). Statistically significant 
results are defined as p < 0.05. Mean 50% inhibitory concentrations (IC50) were estimated using 
GraphPad Prism’s built-in nonlinear regression (least squares) curve fitting. 
2.4 Results 
2.4.1 NH in porcine AVG model 
In the porcine model of AVG established in our laboratory, significant stenosis is usually 
present within 4 weeks after the graft placement (16, 20). In the present study, we conducted a 
time-course analysis to delineate the temporal relationship among NH, angiogenesis, and cell 
proliferation in tissue sections obtained from the venous anastomosis. Progression of the NH 
index (Figure 2.1A), calculated as the ratio of the NH area to the combined area of the graft and 
media, exhibited the same trend as the time-dependent increase in angiogenesis within the NH 





                     
 
Figure 2.1 Time-course of NH development, neovessel density, and proliferation index (PI) 
at the venous anastomosis in a porcine AVG model. A. NH index at the venous anastomosis 
was calculated as the ratio of NH area to the combined area of the graft and media in tissues 
collected at various time points (N = 2, 3, 3, 7, 5 animals at day 1, 7, 14, 21, and 28, respectively). 
*p < 0.05 vs. Day 1. B and C. Anastomotic tissue sections were immunostained to detect 
neovessels and proliferating cells, using antibodies against vWF and Ki-67, respectively, within the 
NH (B) and the adventitia (C). Proliferation index (PI) was determined by dividing the number of 
Ki-67-positive nuclei by the total number of nuclei in the image field. N = 4 animals for each time 
point. *p < 0.05 vs. Day 1 for neovessel density; #p < 0.001 vs. Day 1 for PI. For all panels, each 






increased at postoperative day 7, whereas PI in the NH lesions was significantly increased after 
day 14. This time lag is consistent with the notion that angiogenesis is essential for further NH 
development by supplying oxygen and nutrients to proliferating cells. Interestingly, the neovessel 
density within the adventitia immediately increased after AVG placement, but was followed by a 
sharp decrease after day 7 (Figure 2.1C). The adventitia showed the highest PI at early time 
periods, and after day 7 the increase in adventitial PI largely paralleled changes in neovessel 
density. This temporal profile of proliferating cells in the adventitia was different from that in the NH 
and is consistent with the notion that an early event in NH development is the transformation and 
proliferation of adventitial myofibroblasts which subsequently migrate into the NH and contribute to 
NH formation (18, 35). 
2.4.2 Enhanced expression of pro-NH factors in porcine AVG model 
Expression of various growth factors, including VEGF, PDGF, and basic fibroblast growth 
factor (bFGF), are prominent in the venous NH lesions in specimens obtained from patients with 
failed AVG (29). Our porcine AVG model allows us to investigate whether these mediators of 
proliferation, migration and angiogenesis, and their cognate receptors are prominently expressed 
in the venous anastomosis, and thus, can be implicated as potential causal factors in the early 
development of NH. Figure 2.2 shows that in the NH lesions, VEGF, PDGF-B, and representative 
isoforms of their main receptors, VEGFR-2, PDGFR-, respectively, stained intensely at 14 days 
after AVG placement, compared to the control EJV tissue sections. Moreover, the expression of 







      
 
Figure 2.2 Enhanced expression of VEGF, PDGF, and their cognate receptors at the venous 
anastomosis in a porcine AVG model. Expression of VEGF, VEGFR-2, PDGF-B, and PDGFR- 
in fresh external jugular vein (EJV, left column) and in the venous anastomotic tissues at 14 days 
(middle column) and 28 days (right column) after AVG placement was assessed by 
immunohistochemistry. Rust brown-color indicates positive staining for the indicated proteins. Blue 
structures are hematoxylin-stained nuclei. When compared to fresh EJV, venous anastomotic 
tissues had early (14 days) robust up-regulated expression of these growth factors and their 
cognate receptors, as well as sustained (28 days) over-expression of both growth factor receptors. 
Stained sections were assessed at original magnification x 20, and the scale bar in the top left 






consistent with the notion that VEGF, PDGF, and their receptors play key roles in both early 
development and sustained progression of NH. In addition, PDGF is known to activate other 
growth factor receptors within SMCs, such as epidermal growth factor receptors (EGFRs), 
resulting in the stimulation of multiple tyrosine kinase pathways (19). These observations provide a 
rationale to explore pharmacological interventions to prevent and/or treat NH by inhibiting 
signaling through these growth factor receptors. Accordingly, we examined the effects of sunitinib, 
a small molecule RTK inhibitor, in cell cultures and in an ex vivo perfused vein model. 
2.4.3 Sunitinib inhibits growth factor-induced proliferation of vascular cells 
We have previously demonstrated that among the three PDGF isoforms (PDGF-AA, 
PDGF-AB, and PDGF-BB), PDGF-BB had the greatest potency to stimulate the proliferation of 
both HASMCs and HVSMCs (19). In the present study, HASMCs and HVSMCs were pretreated 
with various concentrations of sunitinib for 1 h, and then stimulated with 50 ng/ml of PDGF-BB for 
48 h. We found that sunitinib inhibited the PDGF-BB-induced proliferation of SMCs in a 
dose-dependent manner, with complete inhibition occurring at ~100 nM (Figure 2.3A). The mean 
IC50 was approximately 10 nM for HASMCs and 40 nM for HVSMCs. Sunitinib almost completely 
inhibited VEGF-induced proliferation of HUVECs at concentrations ≥10 nM (Figure 2.3B), with IC50 
at approximately 8 nM. Cytotoxicity was not apparent under these conditions, as assessed by 
morphologic examination, and was manifested only at concentrations >10,000 nM (data not 
shown). Such high concentrations needed to induce cytotoxicity are consistent with those 




              
 
Figure 2.3 Sunitinib inhibits PDGF-BB-induced proliferation of smooth muscle cells and 
VEGF165-induced proliferation of endothelial cells in vitro. A. Human arterial (HASMC) and 
venous (HVSMC) smooth muscle cells were preincubated with the indicated concentrations of 
sunitinib for 1 h before exposure to PDGF-BB (50 ng/ml) for 48 h. B. Human umbilical vein 
endothelial cells (HUVECs) were preincubated with the indicated concentrations of sunitinib for 1 h 
before exposure to VEGF165 (50 ng/ml) for 48 h. Proliferation was assessed using the 
bromodeoxyuridine incorporation assay. At least six replicate experiments were analyzed for each 
sunitinib concentration. *p < 0.001 vs. PDGF-stimulated no-sunitinib control HASMC, 
PDGF-stimulated no-sunitinib control HVSMC, or VEGF-stimulated no-sunitinib control HUVEC; 




lines, and fetal rat astrocytes (6, 30). 
2.4.4 Sunitinib inhibits PDGF-BB-induced migration of vascular SMCs 
Because NH initiation and development are attributable in part to the migration of cells, 
including medial SMCs and presumably adventitial fibroblasts/myofibroblasts, into the growing NH 
(18, 20, 35), we investigated whether sunitinib also attenuated the migration of HASMCs. Sunitinib 
inhibited the SMC migration stimulated by 50 ng/ml of PDGF-BB in a dose-dependent manner with 
approximately 45% inhibition observed at 1 nM (Figure 2.4). Higher concentrations of sunitinib 
(100 to 1000 nM) did not further inhibit SMC migration.  
2.4.5 Effects of sunitinib on signaling and cell-cycle regulatory 
proteins in vascular SMCs 
The effects of sunitinib on the two main PDGF-stimulated signaling pathways in SMCs, 
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/Akt 
pathways, were characterized using phospho-specific antibodies by Western blotting. As 
previously reported (10, 38), PDGF-BB at 50 ng/ml activated the MAPK and PI3K/Akt pathways, 
as indicated by the robust phosphorylation of ERK1/2, Akt, p70S6k, and rpS6 (Figure 2.5A). 
Sunitinib inhibited the phosphorylation of these prote ins in a dose-dependent manner. 
PDGF-induced phosphorylation of ERK1/2 and Akt was almost completely abolished by 100 nM 
sunitinib, the same concentration that completely inhibited SMC proliferation, as shown in 
Figure2.3A. Sunitinib also inhibited, in a dose-dependent manner, the effects of PDGF-BB on the 







               
 
Figure 2.4 Sunitinib inhibits PDGF-BB-induced migration of smooth muscle cells in vitro. 
HASMCs in a migration-assay chamber were pre-incubated with the indicated concentrations of 
sunitinib for 1 h, and then stimulated with 50 ng/ml of PDGF-BB. HASMCs were allowed to migrate 
for 4 h, and the migrated cells were fluorescence-labeled and counted. At least three replicate 
experiments were analyzed for each sunitinib concentration. *p < 0.001 vs. PDGF-stimulated 










                  
 
Figure 2.5 Sunitinib inhibits PDGF-BB-induced changes in phosphorylation of MAPK and 
PI3K/AKT signaling proteins and expression of cell-cycle regulatory proteins of smooth 
muscle cells in vitro. A. Phosphorylation of the MAPK and the PI3K/Akt pathway after exposure 
of HASMCs to PDGF-BB for 10 min, in the absence or presence of sunitinib, is shown in panels a 
(ERK1/2), c (Akt), e (p70S6k), and g (rpS6). Levels of total ERK1/2, Akt, p70S6k, and rpS6 
proteins are shown in panels b, d, f, and h, respectively. B. Levels of various cell-cycle regulatory 
proteins after exposure of HASMCs to PDGF-BB for 24 h, in the absence or presence of sunitinib, 
are shown in panels a (cyclin D1), b (p21), and c (p27). GAPDH was used as a loading control 




the PDGF-induced expression of cyclin D1, a cyclin-dependent kinase activator and one of the 
earliest mitogenic regulators of cell cycle progression, was nearly completely inhibited (Figure 
2.5B). In contrast, the expression of p21 and p27, cyclin-dependent kinase inhibitors that function 
as antimitogenic regulators, were potently decreased by PDGF-BB stimulation, and this effect was 
reversed by concentrations of sunitinib as low as 10 nM (Figure 2.5B). These observations are 
consistent with the notion that sunitinib inhibits the action of PDGF-BB by suppressing the 
expression of promitotic regulatory proteins and enhancing the expression of cell-cycle 
progression inhibitors. 
2.4.6 Sunitinib inhibits venous NH formation in ex vivo perfused vein culture 
In these experiments, explanted porcine IJV segments exposed to 30% FCS, but with no 
additional growth factors, were perfused ex vivo under defined nonphysiological laminar flow 
conditions for up to 12 days, or kept in static condition as described. All ex vivo cultured vein 
segments appeared intact and patent after 12 days. However, significant NH formation was seen 
only in the perfused vein segments examined histologically at 12 days in culture (Figure 2.6). The 
vein segments in static culture did not develop NH (Supplemental Figure 2.1), suggesting that 
perfusion is sufficient to induce NH. Van Gieson’s staining of elastin fibers of the perfused vein 
sections displayed an overall healthy elastic lamina. Furthermore, there was only a low level of 
apoptotic cell death as assessed by the in situ cleaved caspase-3 assay (Supplemental Figure2.2). 
Cells in the NH lesions appeared disorganized, with elevated levels of proliferation as determined 
by Ki-67 staining. Positive Ki-67 staining, a measure of proliferation, demonstrates the long-term 
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Figure 2.6 NH formation in porcine internal jugular vein (IJV) segments maintained in an ex 
vivo perfused culture. Porcine IJV segments were exposed to nonphysiological WSS in a 
perfused culture system for 12 days. N=3. Cross-sections of ex vivo cultured vein were stained 
with Van Gieson’s stain (elastic fibers and nuclei appear black; collagen appears red). 
Representative cross-sectional views are shown. A and B. IJV segment harvested after 2 days of 
perfused culture shows no NH lesions. Prominent NH lesions were observed after 12 days of 
perfused culture. C. Tissue sections were co-immunostained for smooth muscle -actin 
(appearing green) and Ki-67 (appearing pink in the insert) and examined under confocal 
microscopy at a magnification of x 20. Blue staining denotes cell nuclei and the dashed line 
demarcates the NH lesion from the media. Cells constituting the lesions co-stained positive for 
-actin and Ki-67. D. NH lesions formed at the venous anastomosis of an external jugular vein 
(EJV) in vivo and in ex vivo perfused vein segments were examined for ECs. Tissue sections were 
assessed at a magnification of x 20. Blue staining denotes cell nuclei. NH lesions formed in EJV 4 
weeks after graft implantation had an intact endothelium that stained positive for vWF (appearing 
green in the insert). NH lesions formed in IJV after 12 days of ex vivo perfused culture were 
negative for vWF staining. 
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viability of ex vivo cultured veins. In addition, cells were immunoreactive for smooth muscle -actin, 
suggesting that the cells occupying the NH lesions primarily resulted from the migration and 
proliferation of de-differentiated SMCs and/or transformed myofibroblasts (Figure 2.6C). These 
histological features are similar to those observed in the NH lesions in our porcine model in vivo. It 
is important to note, however, that we did not detect an intact endothelium nor any neovessels in 
the NH lesions (Figure 2.6D). The loss of EC in the venous segment upon ex vivo organ culture 
was similar to that previously reported by others (5, 11). Notwithstanding the loss of ECs, the key 
features of NH in our ex vivo model are the same observed in the in vivo model, including 
proliferation, possible migration, and disorganized appearance of the SMCs. Sunitinib (100 nM) 
markedly inhibited NH lesion formation in the ex vivo perfused vein segments (Figure 2.7A). The 
mean I/M area ratio decreased in sunitinib-treated vein segments, as shown in Figure 2.7B (0.38 ± 
0.24 vs. 0.13 ± 0.05; N = 3 each; p < 0.15) although this difference did not reach statistical 
significance. The mean I/L area ratio (Figure 2.7B), which takes into consideration variations in the 
lumen diameters, was significantly decreased (0.45 ± 0.25 vs. 0.04 ± 0.02; N = 3 each; p < 0.05). 
The low level of apoptotic cell death indicates that the inhibitory effect of sunitinib on NH formation 
was not the result of cell death. 
2.5 Discussion 
In human specimens retrieved from patients with failed AVGs as well as in tissues 
obtained from our porcine model of AVG stenosis, angiogenesis has been shown to occur within 






           
 
Figure 2.7 Sunitinib inhibits NH formation in porcine internal jugular vein (IJV) segments 
maintained in an ex vivo perfused culture. A. Representative histological images of the tissue 
cross-sections (by Van Gieson’s stain, x 10) revealed healthy vein walls in both untreated control 
(panel a) and sunitinib (100 nM)-treated vein segments (panel b) perfused for 12 days. B. The 
intima-to-media area ratio (I/M ratio) decreased from 0.38 ± 0.24 in the untreated vessels (N = 3) 
to 0.13 ± 0.05 in the sunitinib-treated vessels (N = 3, p < 0.15). The intima-to-lumen area ratio (I/L 







expression of VEGF and VEGFRs (21, 28, 29, 32). Our in vivo time-course study showed that the 
density of neovessels within NH lesions gradually increased with NH progression (Figure 2.1). The 
neovessels likely promote NH development by supplying oxygen and nutrients to the highly 
proliferative cells, as well as providing a conduit for inflammatory cells that release pro-proliferative 
and promigratory mediators. Although there was a marked increase in neovessel density in the NH 
lesions, few Ki-67-positive proliferating cells were observed in the early period (Figure 2.1B). Thus, 
the mechanism(s) by which early neovessels develop in NH lesions is likely not due to cell 
proliferation and may result from cell migration. At the same time, an early increase in neovessel 
density and cell proliferation in the adventitia was observed, followed by an abrupt decrease of 
both features in that location (Figure 2.1C). While these observations do not prove causality, the 
strong temporal associations suggest that adventitial angiogenesis and proliferation contribute to 
subsequent angiogenesis and cell proliferation in the NH lesions. Enhanced adventitial 
angiogenesis soon after AVG implantation may be the consequence of wound-healing activities 
following surgical trauma, but the exact underlying mechanism(s) requires further investigation. 
It has been proposed that multiple pathogenic factors may contribute to NH development 
after AVG placement (21). However, the localized nature of NH with strong predisposition to form 
at the venous anastomosis points toward abnormal blood flow as a crucial pathogenic factor, as 
shunting of arterial blood flow directly into the vein exposes the vein to an aberrant hemodynamic 
environment. Previous biomechanics studies have shown that manipulation of certain 
hemodynamic parameters in the vein, such as hydrostatic pressure or WSS, can induce 
pathological vessel remodeling, including NH development and wall hypertrophy (11). Here, we 
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exploited this concept and demonstrated that nonphysiological levels of WSS were associated 
with NH formation in the explanted porcine vein segments, resembling the lesions observed in vivo. 
Specifically, we found that the ex vivo NH lesions were comprised primarily of disorganized, 
proliferating cells that stained positive for smooth muscle -actin. Importantly, neither untreated 
nor sunitinib-treated perfused vein segments showed any notable increase in apoptosis, 
compared to fresh veins or venous anastomotic tissue sections retrieved from our animal model. 
One difference between the NH lesions in cultured vein (IJV) segments after 12 days of perfusion 
and the NH at the anastomotic vein (EJV) segments in vivo was the lack of ECs in the cultured 
vein segments. This endothelial loss was similar to the observation of Clerin et al. and Gusic et al. 
(5, 11). In these studies, spontaneous endothelium denudation under certain culture conditions 
during the ex vivo culture of porcine artery and vein segments is described. Further investigations 
are necessary to determine the cause of endothelial loss and its consequences in the ex vivo 
culture model. 
The value of this ex vivo culture model lies in examining explanted whole-vessel segments 
under well-defined hemodynamic environments hypothesized to cause NH in vivo. The ex vivo 
model also provides the opportunity for cell migration and cross-talk within the architectural 
framework of the native vessel that may be critical for NH development. Finally, this system can be 
used to assess the responsiveness of the whole-vessel to pharmacological agents.  
Antiproliferative, anti-inflammatory and/or antithrombotic agents are logical targets in the 
development of therapeutic strategies to inhibit NH formation in AVG stenosis (15, 21). In our study, 
the animals with AVG were maintained on aspirin and clopidogrel to prevent early thrombosis. 
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Despite successful prevention of early thrombosis, robust NH develops in our porcine model 
(Figure 2.1). Two antiproliferative agents, paclitaxel and rapamycin, have shown efficacy in 
inhibiting NH formation in animal AVG models on background aspirin/clopidogrel therapy (17, 21, 
22, 34). Paclitaxel and rapamycin directly suppress cell proliferation by stabilizing nuclear mitotic 
microtubules and inhibiting the mammalian target of rapamycin, respectively (17, 22, 34). The 
present study explored the potential of targeting different mechanisms of NH formation by 
exploiting the unique properties of sunitinib. Although sunitinib is known to inhibit the mobility of 
ECs and certain cancer cells (4, 24, 36, 39), this is the first report that sunitinib inhibits growth 
factor-stimulated proliferation and migration of normal vascular SMCs (Figures 2.3 and 2.4). We 
also demonstrated the efficacy of sunitinib in attenuating the formation of venous NH lesions in the 
ex vivo perfused blood-vessel culture system that reproduces the pathological WSS observed in 
vivo.  
In the context of AVG-induced NH, sunitinib probably exerts multiple effects by 
antagonizing a variety of RTKs in SMCs and ECs. Major molecular targets of sunitinib include all 
receptors for PDGF and VEGF, stem-cell factor receptor (KIT), glial cell-derived neurotrophic 
factor receptor (REarranged during Transfection or RET), colony-stimulating factor 1 receptor 
(CSF-1R), and Fms-related tyrosine kinase-3 receptor (FLT3), most of which are involved in 
pro-oncogenic pathways (3, 9, 13, 26). Among these receptors, PDGFRs and VEGFRs, as well as 
their respective ligand growth factors, are substantially expressed in the NH lesions obtained from 
the venous anastomotic tissues in our porcine AVG model (Figure 2.2). The expression of other 
receptors listed above has not been examined in NH. In this study, we demonstrated that sunitinib 
55 
 
blocked signal transduction downstream of RTKs by inhibiting the phosphorylation of key proteins 
in the MAPK and the PI3K/Akt pathways in SMCs. In addition, we report that sunitinib treatment 
reversed PDGF-induced changes in the expression of key cell-cycle regulatory proteins. The 
effects of sunitinib on the MAPK and PI3K/Akt pathways in vascular SMCs, and especially its 
effects on p70S6k and rpS6, have not been previously reported. 
In conclusion, sunitinib was demonstrated to be effective in inhibiting several cellular and 
intracellular signaling processes associated with NH development in AVGs. Furthermore, sunitinib 
attenuated NH formation induced by nonphysiological mechanical cues in an ex vivo perfused 




















       
 
Supplemental Figure 2.1 Vein segments in static culture did not develop NH. Porcine EJV (a) 
and IJV (b) segments were cut longitudinally to expose the lumen and cultured in static condition 
for 14 days in DMEM containing 30% FCS. Cross-sections of cultured vein segments were stained 























       
Supplemental Figure 2.2 Low level of apoptotic cell death in porcine jugular veins assessed 
by the in situ cleaved caspase-3 assay. Apoptotic cells (appearing yellow) in the fresh porcine 
EJV (panel a) were undetectable, in contrast to NH lesions formed in the EJV in a porcine AVG 
stenosis model (b). Both untreated control (panel c) and sunitinib-treated (panel d) porcine IJV 
segments perfused ex vivo for 12 days exhibited low levels of apoptosis. Blue staining denotes cell 








1. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and 
solutions. Kidney Int 62: 1109-1124, 2002. 
 
2. Asif A, Gadalean FN, Merrill D, Cherla G, Cipleu CD, Epstein DL, Roth D. Inflow stenosis in 
arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 67: 1986-1992, 2005.  
 
3. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 
884-896, 2007. 
 
4. Christensen JG. A preclinical review of sunitinib: a multitargeted receptor tyrosine kinase 
inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18 (Suppl 10): x3-x10, 2007. 
 
5. Clerin V, Gusic RJ, O'Brien J, Kirshbom PM, Myung RJ, Gaynor JW, Gooch KJ. Mechanical 
environment, donor age, and presence of endothelium interact to modulate porcine artery viability 
ex vivo. Ann Biomed Eng 30: 1117-1127, 2002. 
 
6. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo 
JS. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. 
Neuro Oncol 9: 412-423, 2007. 
 
7. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez 
MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman 
JS, Meyers CM, Kusek JW, Feldman HI, Dialysis Access Consortium Study Group. Effect of 
clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. 
JAMA 299: 2164-2171, 2008. 
 
8. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, 
Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, 
Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, 
Meyers CM, Kusek JW, Feldman HI; DAC Study Group. Effect of dipyridamole plus aspirin on 
hemodialysis graft patency. N Engl J Med 360: 2191-2201, 2009. 
 
9. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, 
Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, 
Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, 
Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. 




10. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. 
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated 
phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995.  
 
11. Gusic RJ, Myung R, Petko M, Gaynor JW, Gooch KJ. Shear stress and pressure modulate 
saphenous vein remodeling ex vivo. J Biomech 38: 1760-1769, 2005. 
 
12. Joddar B, Shaffer RJ, Reen RK, Gooch KJ. Arterial pO2 stimulates intimal hyperplasia and 
serum stimulates inward eutrophic modeling in porcine saphenous veins cultured ex vivo. 
Biomech Model Mechanobio. 10: 161-175, 2011.  
 
13. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, 
Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, 
Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase 
inhibitor selectivity. Nat Biotechnol 26: 127-132, 2008. 
 
14. Kelly BS, Heffelfinger SC, Whiting JF, Miller MA, Reaves A, Armstrong J, Narayana A, 
Roy-Chaudhury P. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft 
stenosis. Kidney Int 62: 2272-2280, 2002. 
 
15. Kent KC, Liu B. Intimal hyperplasia—still there after all these years! Ann Vasc Surg 18: 
135-137, 2004. 
 
16. Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, 
Blumenthal DK, Kern SE, Cheung AK. Efficacy of local dipyridamole therapy in a porcine model of 
arteriovenous graft stenosis. Kidney Int 69: 2179-2185, 2006. 
 
17. Lee BH, Lee JE, Lee KW, Nam HY, Jeon HJ, Sung YJ, Kim JS, Lim HJ, Park JS, Ko JY, Kim 
DJ. Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft 
stenosis. Nephrol Dial Transplant 22: 2800-2804, 2007. 
 
18. Li G, Chen SJ, Oparil S, Chen YF, Thompson JA. Direct in vivo evidence demonstrating 
neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation 
101: 1362-1365, 2000. 
 
19. Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK. PDGF-induced proliferation in 
human arterial and venous smooth muscle cell: Molecular basis for differential effects of PDGF 




20. Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung 
AK. Cellular and morphological changes during neointimal hyperplasia development in a porcine 
arteriovenous graft model. Nephrol Dial Transplant 22: 3139-3146, 2007. 
 
21. Li L, Terry CM, Shiu YE, Cheung AK. Neointimal hyperplasia associated with synthetic 
hemodialysis grafts. Kidney Int 74: 1247-1261, 2008. 
 
22. Masaki T, Rathi R, Zentner G, Leypoldt, JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, 
Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK. Inhibition of neointimal 
hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 66: 
2061-2069, 2004. 
 
23. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 190: 
300-309, 2000. 
 
24. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor 
SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, 
but has little effect on existing tumor vessels. Angiogenesis 7: 225-233, 2004.  
 
25. Rekhter M, Nicholls S, Ferguson M, Gordon D. Cell proliferation in human arteriovenous 
fistulas used for hemodialysis. Arterioscler Thromb 13: 609-617, 1993. 
 
26. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis 
inhibitor. Biochem Biophys Res Commun 356: 323-328, 2007. 
 
27. Rotmans JI, Velema E, Verhagen HJ, Blankensteijn JD, Kastelein JJ, de Kleijn DP, Yo M, 
PasterKamp G, Stroes ES. Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine, 
bilateral, carotid arteriovenous graft model. J Surg Res 113: 161-171, 2003. 
 
28. Roy-Chaudhury P, Kelly BS, Melhem M, Zhang J, Li J, Desai P, Munda R, Heffelfinger SC. 
Vascular access in hemodialysis: issues, management, and emerging concepts. Cardiol Clin 23: 
249-273, 2005.  
 
29. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger 
SC. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59: 
2325-2334, 2001. 
 
30. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small 
molecule receptor tyrosine kinase inhibitor blocks function of the ATP-binding cassette (ABC) 




31. Singh P, Robbin ML, Lockhart ME, Allon M. Clinically immature arteriovenous hemodialysis 
fistulas: Effect of US on salvage. Radiology 246: 299-305, 2008. 
 
32. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular 
hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, 
immunocytochemical, light and electron microscopic assessment. Circulation 80: 1726-1736, 
1989. 
 
33. Terry CM, Blumenthal DK, Sikharam S, Li L, Kuji T, Kern SE, Cheung AK. Evaluation of 
histological techniques for quantifying hemodialysis arteriovenous (AV) graft hyperplasia. Nephrol 
Dial Transplant 21: 3172-3179, 2006. 
 
34. Terry CM, Li L, Li H, Zhuplatov I, Blumenthal DK, Kim SE, Owen SC, Kholmovski EG, Fowers 
KD, Rathi R, Cheung AK. In vivo evaluation of the delivery and efficacy of a sirolimus-laden 
polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft 
stenosis. J Control Release 160: 459-467, 2012. 
 
35. Tomas JJ, Stark VE, Kim JL, Wolff RA, Hullett DA, Warner TF, Hoch JR. Beta 
galactosidase-tagged adventitial myofibroblasts tracked to the neointima in healing rat vein grafts. 
J Vasc Res 40: 266-275, 2003. 
 
36. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, 
Carmeliet P, Jiménez W, Morales-Ruiz M. Antiangiogenic treatment with sunitinib ameliorates 
inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919-1926, 
2007. 
 
37. United States Renal Data System, USRDS 2004 Annual Data Report: Atlas of Chronic Kidney 
Disease and End-Stage Renal Disease in the Unites States, National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004. 
 
38. van Dijk MC, Hilkmann H, van Blitterswijk WJ. Platelet-derived growth factor activation of 
mitogen-activated protein kinase depends on the sequential activation of 
phosphatidylcholine-specific phospholipase C, protein kinase C-zeta and Raf-1. Biochem J 325: 
303-307, 1997.  
 
39. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal 






GENE EXPRESSION ANALYSES OF VEIN REGIONS WITH DIFFERENT  
SUSCEPTIBILITIES TO NEOINTIMAL HYPERPLASIA IN A PORCINE  
 
ARTERIOVENOUS GRAFT STENOSIS MODEL  
 
3.1 Abstract 
It is widely accepted that arteriovenous hemodialysis graft (AVG) stenosis develops 
predominantly as a result of neointimal hyperplasia (NH) formation in susceptible venous 
anastomotic regions. This important clinical problem has not been resolved due to our limited 
understanding of the molecular processes involved in the pathophysiology. It is known that the 
vein regions most susceptible to NH are at the anastomosis, whereas juxta-anastomotic vein 
regions are relatively resistant to NH. We hypothesize that the gene expression profiles of the 
NH-prone and nearby NH-resistant vein will be different after graft placement and that these 
differences could provide important insights into possible therapeutic targets to prevent AVG 
stenosis. To test this hypothesis, we evaluated the global genomic profiles of NH-prone and 
NH-resistant vein regions in a porcine model of AVG stenosis. Using a porcine microarray, gene 
expression changes in these two distinct vein regions were examined at 5 and 14 days following 
graft placement. Global genomic changes were more dramatic in the NH-prone vein region than in 
the NH-resistant region at both time points. In the NH-prone region, genes related to regulation of 
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cell proliferation were most enriched among the significantly up-regulated genes at day 5, while 
up-regulated genes associated with osteo/chondrogenic vascular remodeling were most enriched 
at day 14. At both time periods, genes related to muscle phenotype were significantly 
down-regulated. In the NH-resistant vein region, genomic changes were less prominent. These 
results provide insights into the spatial and temporal genomic modulation underlying NH formation 
in AVG, and suggest potential therapeutic strategies to prevent and/or limit AVG stenosis.  
3.2 Introduction 
Synthetic arteriovenous hemodialysis grafts (AVG) are widely used vascular access 
conduits for hemodialysis. AVGs are, however, prone to stenosis and subsequent thrombosis and 
occlusion, leading to primary failure rates that are reported to be 50% and 75% at 1 and 2 years 
after implantation, respectively (1-4). Localized neointimal hyperplasia (NH) that forms most 
frequently at the graft-venous anastomosis (hereafter referred to as the venous anastomosis; VA), 
and less commonly at the graft-arterial anastomosis (arterial anastomosis), is known to be the 
predominant cause of AVG failure (5). Histological examination of human specimens and tissues 
from animal AVG stenosis models reveal that the NH lesions are highly cellularized with excessive 
extracellular matrix (ECM) proteins, inflammatory cells, and micro-neovessels. These changes in 
the vessel wall can be observed shortly after the AVG placement and progressively increase over 
time (3, 5, 6). There are currently no therapies to prevent or treat NH formation to achieve 
long-term AVG patency. Development of effective therapies for NH is impeded largely by our 
limited understanding of the mechanisms by which the vessel remodels in response to stimuli. It is 
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postulated that upon graft placement, the venous anastomosis harbors multiple pathogenic 
components that may play causal roles in the NH formation process, which include enhanced 
wound healing and inflammatory activities, nonphysiological hemodynamic stress, and the 
absence of the protective adventitia and endothelium (5, 7-11). As such, venous NH formation may 
be the result of complex interplay among all residing pathogenic factors, although the precise 
underlying cellular and molecular events are far from completely understood.  
In a porcine model of AVG stenosis that is established in our laboratory, NH formation is 
localized to the VA and is rarely observed in the distant upstream or downstream vein regions of 
the VA (i.e., vein region only 1 cm away from the VA, hereafter referred to as the proximal vein 
(PV)). Because pathogenic factors operating early on in the process of NH formation are expected 
to trigger a spectrum of gene expression profiles, we hypothesize that the gene expression profiles 
of the NH-prone (VA) and nearby NH-resistant (PV) vein regions will be different after graft 
placement and that analysis of the gene expression patterns in the NH-prone region will provide 
clues regarding potential therapeutic targets to prevent NH. If the VA region is more prone to NH, 
one possible indication is that there would be a larger number of genes with significantly altered 
expression compared to the PV region, and that these genes are involved in NH development. To 
test this hypothesis, we employed a porcine global gene expression microarray to investigate the 
differential genomic features of the NH-prone vein region and the NH-resistant region relative to a 
common reference control vein at early time periods following AVG placement. To our knowledge, 
this is the first investigation of the differential global genomic profiles in these distinct vein regions 
in a porcine or in other models of AVG.  
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3.3 Materials and Methods 
3.3.1 Materials 
All reagents used for RNA isolation including RNAlater solution, QIAzol Lysis Reagent, 
and the miRNeasy RNA extraction kit were purchased from Qiagen Inc. (Valencia, CA). Reagents 
used for microarray labeling and hybridizations were provided by the Microarray Core Facilities at 
the University of Utah. The porcine 44K (v1) oligonucleotide microarray slides representing 43,803 
probes were purchased from Agilent Technologies (Palo Alto, CA). All reagents used for RT-PCR 
were obtained from Applied Biosystems (Foster City, CA).    
3.3.2 Porcine model of AVG stenosis 
The porcine AVG stenosis model employed in our laboratory has been previously 
described (3, 12). Animal surgeries were performed in accordance with a protocol that was 
approved by the Institutional Animal Care and Use Committees (IACUCs) at the Veterans Affairs 
Salt Lake City Health Care System and the University of Utah. Female Yorkshire pigs (Sigma 
Livestock, Salt Lake City, UT) weighing 30-35 kg were used to implant expanded 
polytetrafluoroethylene (ePTFE) grafts unilaterally between the ipsilateral external jugular vein 
(EJV) and the common carotid artery (CCA), creating both graft-end-to-vessel-side arterial and 
venous anastomoses. Sodium heparin was administered during the surgery and aspirin 
(Pharmaceutical Formulations, Edison, NJ), clopidogrel (Bristol-Myers Squibb, New York, NY), 
and enrofloxacin (Bayer, Pittsburgh PA) were administered peri-operatively. Graft patency was 
monitored by Doppler ultrasound until the animals were euthanized at the two indicated time 
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points, 5 or 14 days post-graft placement. A total of ten operated animals were used to perform 
gene expression studies. Two animals were subjected to premature euthanasia due to early 
occlusion of the ePTFE graft, and therefore were not utilized for the microarray experiments. Each 
time period was N = 4 animals (replication at the level of biology).  
Grafted and native vein segments (1 cm each, including a vein segment from the 
unoperated control EJV on the contralateral side of each operated animal) were retrieved 
according to the scheme shown in Figure 3.1, and were immediately immersed in RNAlater 
solution (Qiagen Inc., Valencia, CA). Immersed vein segments were then kept at 4 C for no longer 
than 2 weeks before tissue samples were processed for total mRNA extraction as described 
below.   
3.3.3 RNA extraction, microarray hybridization, and data analysis 
Total mRNA was extracted from collected vein sample lysates using the miRNeasy Mini 
Kit (Qiagen). A small portion (≤ 50 mg) of each vein segment, including the roof and the floor walls 
as well as any tissue that might have grown inside the lumen, was minced using razor blades. For 
homogenization, minced samples were further disrupted using a TissueLyser (Qiagen). DNase 
treatment was included in the extraction procedure to confirm further purification of RNA. RNA 
concentrations were measured using a spectrophotometer (LAMBDA Bio, PerkinElmer, Waltham, 
MA). The quality of mRNA was determined using an Agilent Bioanalyzer 2100 (Agilent 
Technologies) and mRNA integrity was assessed by the RNA integrity number (RIN). If the amount 







                  
 
Figure 3.1 Diagrammatic representation of the venous anastomosis (VA) and a vein 
segment downstream of the VA (PV; proximal vein) of an operated EJV in a porcine AVG 
stenosis model. NH formation predominantly occurs at the VA and less likely at juxta-anastomotic 
vein regions, such as in the distal or the proximal EJV segments (distal or proximal relative to the 
location of the heart). The VA and PV (1 cm length each) segments were collected at day 5 or day 
14 following graft placement. An unoperated EJV segment (1 cm length) from the contralaetral 
side of each animal was also collected as a common reference control sample, which is not shown 
in the diagram. Samples were immediately immersed in RNAlater solution upon dissection. Arrows 









than 5, RNA extraction was repeated for those specific samples with banked tissue samples. 
The Agilent Two-Color Quick Amp Labeling Kit was used to generate fluorescently-labeled 
complimentary RNA (cRNA) targets. Agilent RNA spike-in controls were combined with input total 
mRNA samples, which were then primed with oligo (d)T-T7 RNA polymerase promoter 
oligonucleotide sequences. Complementary DNA (cDNA) synthesis was accomplished through 
the addition of M-MLV-Reverse Transcriptase. Following cDNA synthesis, T7 RNA polymerase and 
cyanine 3- or cyanine 5-CTP were combined with the reaction mixtures to simultaneously amplify 
the materials to generate cRNA targets. Microarray hybridizations were performed using Agilent 
SureHyb Hybridization chambers according to manufacturer’s instructions. Hybridization 
chambers were loaded onto a rotisserie hybridization oven and were incubated at 65 C for 17 h, 
and then washed in Gene Expression Wash Buffer. Microarray slides were briefly dipped in a 
solution of acetonitrile and then dried. Slides were scanned in an Agilent G2505C Microarray 
Scanner at 5 m resolution, which allows simultaneous detection of cyanine 3 and cyanine 5 
signals on the hybridized slide. Finally, scanned data were loaded into Agilent Feature Extraction 
Software (v10.5) for data analysis.  
The quality of the microarray data was evaluated by examining the quality control report 
produced by the Agilent microarray platform. Every array performed passed all eleven quality 
metrics in Agilent’s QC report. Microarray data were filtered to remove values from control features 
and any features flagged as nonuniform or population outliers. Remaining features from each 
microarray probe were averaged to yield a single value for each probe. Resulting intensity values 
were log2-transformed and normalized using median centering.  
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Normalized data for all probes were clustered in R with the hclust ( ) function, using 
Euclidean distance and Ward’s method. This clustering revealed a batch effect in the data that 
correlated with the date on which the data were generated. Microarray data were processed in 
multiple batches over the course of 2 years due to technical and time constraints, and clustering of 
normalized data revealed a batch effect that correlated with the date on which the data were 
generated (data not shown). A batch-adjustment analysis was performed using ComBat analysis 
software (13). Specifically, each microarray was described in a parameter file by the following 
parameters: sample name, batch number (1 through 4), origin of tissue, and time point of 
treatment (5 days or 14 days). Given the parameter file and a matrix of normalized microarray data, 
the ComBat software ComBat estimated factors that correlated with batch number (1 through 4), 
origin of tissue, and time point of tissue retrieval, and subtracted the batch-related factors while 
leaving the effects of other covariates. Following batch adjustment, hierarchical clustering 
revealed that the batch effects were largely controlled, with samples clustering primarily by origin 
of tissue, and then by time point. Batch-adjusted data were uploaded into GeneSifter® Analysis 
Edition v3.7 (http://www.genesifter.net, Geospiza, Seattle, WA) for statistical analysis. 
Transcripts with mean fold-changes ≥ 4.0 and adjusted ANOVA p < 0.05 (Benjamini and 
Hochberg correction) in either the VA or the PV segment (or both) compared to their corresponding 
transcripts from common EJV control segments were selected for subsequent analysis. The rather 
stringent fold-change cut-off with moderate statistical significance across 4 pigs allowed us to 
efficiently explore the massive microarray data for understanding the most relevant biological 
significance. Our selection threshold also takes normal gene expression variations reported in the 
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literature into consideration (14-16). For example, studies report that there can be as much as 
4-fold random fluctuations as physiological variance for less tightly regulated genes, such as most 
of the housekeeping genes, in human tissues. In addition, a threshold of 2-fold or less has been 
shown to be statistically invalid even for duplicated experiments (15).  
After filtering, there were 1392 and 787 transcripts, which included the unannotated 
transcripts with no accession numbers at day 5 and day 14 post-graft placement, respectively. The 
Agilent porcine 44K (v1) 60-mer oligonucleotide microarray platform contains 43,803 representing 
probes. A significant number of probes in this porcine array were unannotated transcripts without 
accession numbers and could therefore not be utilized for Gene Ontology (GO) studies. These 
transcripts were only described by the unique Tentative Consensus (TC) identifiers derived from 
The Institute for Genomic Research (TIGR) Gene Indices, a collection of species-based 
databases that was constructed for analyzing genes and expressed sequence tag (EST) 
sequences. Therefore, these transcripts were excluded from further analyses. For incompletely 
annotated porcine transcripts with accession numbers, we used nucleotide basic local alignment 
search tool (BLAST) to determine similar sequences in other species using sequence matches 
above a specified cut-off threshold (≥ 50% matching query-subject coverage and E-value ≤ 10-4). 
In most cases, the annotated “hit” sequence with the highest total score that fulfilled our specified 
cut-off threshold criteria was selected. To extract biological information from the patterns of gene 
expression associated with NH, we used GATHER for identification of enriched biological themes 
(19). GATHER, a Gene Annotation Tool to Help Explain Relationships, is a web-based ontology 
algorithm that detects enrichment of GO terms and signatures from high-throughput genomic 
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experiments. Annotated transcripts significantly altered in each of the two vein regions were 
separately subjected to GATHER analysis. Also, up- or down-regulated transcripts were 
separately analyzed. Although there seems to be no gold standard for Bayes Factor cut-offs (a 
Bayes Factor it is not an absolute decision value as long as it is a positive value), studies have 
reported that a cut-off of 6 most likely balances false positives and false negatives. A Bayes Factor 
cut-off of at least 6 was applied to all analyses (19). 
3.3.4 Quantitative reverse transcriptase-PCR 
Using the same mRNA samples used for microarray studies, we assessed the expression 
of seven genes of interest by quantitative RT-PCR. Conversion from mRNA to cDNA was 
conducted using the High Capacity RNA-to-cDNA kit (Applied Biosystems) with a reaction volume 
of 20 L. All primer and probe sets were obtained from the inventoried Taqman® Gene Expression 
Assay for Sus scrofa (Applied Biosystems). The PCR reaction in a 20 L reaction volume was 
carried out by initializing (50 C, 2 min followed by 95 C, 10 min), 40 cycles of denaturation (95 C, 
15 s), and annealing and extension (60 C, 1 min) using an Applied Biosystems 7300 Real-Time 
PCR System. PCR amplification efficiencies were similar for all genes tested. Relative gene 
expression was normalized to the expression of the housekeeping gene, beta-2 microglobulin 







3.4.1 Spatial and temporal gene expression changes between the VA 
and PV at day 5 and day 14 post-graft placement 
We compared the global gene expression profile changes after filtering the transcripts that 
satisfied our selection threshold (mean fold-changes ≥ 4.0 and ANOVA p < 0.05 in either the VA or 
the PV segment (or both) compared to the corresponding control EJV samples) at day 5 and day 
14 following AVG placement. Our threshold criteria applied to the microarray data identified 1392 
and 787 transcripts differentially expressed at day 5 and day 14, respectively, which included the 
unannotated transcripts with no accession numbers (Figure 3.2; full clustering is shown in 
Supplemental Figure 3.1). Figure 3.2 illustrates the spatial and temporal global gene expression 
profiles of the filtered transcripts presented as a microarray heat map (each group N = 4). 
Clustering of samples showed that the VA and PV are more similar to each other than to the 
unoperated control EJV segment. At day 14, fewer transcripts were significantly regulated 
compared to day 5. This temporal difference of the number of significantly altered transcripts may 
reflect the complexity of very early molecular events (e.g., within a few days) that may contribute to 
the initial stages of NH development. The unannotated transcripts with no accession numbers 
were excluded from further data analyses, leaving 801 and 447 filtered transcripts at day 5 and 
day 14, respectively. 
In Figure 3.3, Venn diagrams of the 801 and 447 filtered transcripts at day 5 and day 14, 
respectively, indicate that a substantial number of significantly regulated transcripts were shared 






Figure 3.2 The spatial and temporal gene expression profile changes between the VA and 
PV regions at day 5 (A) and day 14 (B) post-graft placement. GeneSifter identified 1392 and 
787 transcripts that met our selection threshold from four independent microarray experiments at 
day 5 and day 14, respectively. Sample clustering indicates that the VA and PV are more similar to 
each other than to the unoperated control EJV segment. The microarray heat map shows part of 
the most greatly regulated portions of the VA and PV cluster analyses. The color-coded scale for 






    
 
Figure 3.3 Venn diagrams indicating the degree of overlap between the spatially and 
temporally regulated transcripts in the VA and PV regions. The degree of overlap of 801 and 
447 filtered transcripts which are significantly regulated at day 5 and day 14, respectively, is 
illustrated. (A) At both time points following AVG placement, substantial numbers of transcripts 
whose expressions were up- (red) or down-regulated (green) are regulated in common between 
the VA and PV. (B) The numbers of up- (red) or down-regulated (green) transcripts that temporally 
overlap between day 5 and day 14 in each vein region are shown. Overall, greater number of 
transcripts was differentially regulated in the VA than in PV, and at 5 days than at 14 days 




transcripts regulated in one direction in one vein region or time point were regulated in the same 
direction in the other. Overlapping transcripts satisfied the threshold criteria in both vein regions 
(Figure 3.3A) or at both time points (Figure 3.3B). These findings suggest that certain molecular 
events are regulated in common between the two distinct hemodynamic environments. It is also 
conceivable that there are both early transient gene expression changes as well as early 
molecular events that were sustained into day 14.  
3.4.2 Up-regulated genes with cell proliferation-associated annotations 
were enriched in the VA and PV at day 5 post-graft placement 
We performed GATHER analysis to investigate potential functional relationships of 
significantly altered transcripts in each of the two vein regions. Because a large number of the 
gene transcripts selected were incompletely annotated, nucleotide BLAST was used to infer the 
identity of those porcine transcripts having accession numbers. These incompletely annotated 
genes were added to those that were fully annotated for subsequent analysis. Among the filtered 
transcripts described above, incompletely annotated transcripts with no significant BLAST 
alignments were discarded, and a total of 625 and 387 transcripts for the VA and PV, respectively, 
were subjected to GATHER analysis for the day 5 time point. Up- or down-regulated transcripts 
from the microarray data were analyzed separately. 
The most significant (Bayes Factor ≥ 6) functional annotations of up-regulated transcripts 
in the VA represented cell cycle regulation GO terms that putatively participate in the regulation of 




Table 3.1 Over-represented Gene Ontology (GO) terms for significantly up-regulated genes 
at 5 days post-graft placement in the VA (A) and PV (B). (A) At day 5 in the VA, GATHER 
analysis of the 283 up-regulated transcripts representing 261 genes relative to the control EJV is 
shown. Significant annotations with Bayes Factor of at least 6 all denote cell cycle-related events. 
(B) At day 5 in PV, GATHER analyzed 162 up-regulated transcripts representing 151 genes 
relative to the control EJV. A number of significant annotations also displayed association with cell 
cycle-related events. 
 





cyclin-dependent kinases (e.g., CCNA2, CCNB1, CCNF, CDC2), nuclear components of mitosis 
and cytokinesis (e.g., BRRN1, CENPF, KIF23, KNTC2), and transcription factors known to play 
roles in regulation of cell survival (e.g., E2F8, WT1) (Supplemental Table 3.1). Kyoto Encyclopedia 
of Genes and Genomes (KEGG) analysis showed that the cell cycle pathway was a significant 
pathway activated in the VA at day 5, further supporting the GO analysis. Analysis using the 
TRANSFAC module identified genes with nuclear factor Y (NFY) binding sites as having a 
meaningful Bayes Factor (Table 3.1A). For up-regulated transcripts in the PV at day 5, a number of 
the cell cycle regulation terms observed in the VA were also commonly identified as significantly 
enriched but with lower Bayes Factors (Table 3.1B). These annotations were associated with 
several of the same genes that contributed to the cell cycle regulation terms in the VA 
(Supplemental table 3.1). No KEGG pathway terms or TRANSFAC components were identified 
with a meaningful Bayes Factor in the PV at day 5. 
3.4.3 Enrichment of up-regulated genes in the osteo/chondrogenesis 
pathways in the VA and PV at day 14 post-graft placement 
At day 14, progression of venous NH lesions becomes more prominent as the vessels 
adapt to the new pathological environment. At the molecular level, we expected that the spectrum 
of expressed genes during this period to be different from that of the earlier 5-day period. A total of 
336 and 111 transcripts for the VA and PV, respectively, were subjected to GATHER analysis for 
the day 14 time point. In the VA, GO analysis of up-regulated transcripts revealed that genes 
associated with a group of related annotations (Skeletal Development, Ossification, and Bone 
78 
 
Remodeling) were significantly enriched (Table 3.2A). Genes contributing to these terms were also 
associated with less refined GO classes such as Morphogenesis, Organogenesis, and 
Development in Table 3.2A. When each gene in these gene sets was explored, we found that 
several key components of the osteo/chondrogenic pathways (e.g., CDH11, COL11A1, IBSP, 
SPP1) together with the upstream master transcriptional regulators of bone (RUNX2) and cartilage 
(SOX9) differentiation were substantially up-regulated in the VA (Supplemental Table 3.1). 
ECM-receptor interaction was identified as a significant pathway activated in the VA at day 14, and 
AP-1 transcription factor binding sites were identified in a large number of up-regulated genes. In 
the PV at day 14, several of the osteo/chondrogenic pathway genes observed in the VA were also 
significantly up-regulated, and were reflected in the enriched annotations (Table 3.2B). These 
findings clearly suggest that up-regulation of vascular calcification-related pathways may be 
important in the pathological development of NH following AVG placement. 
3.4.4 Down-regulation of genes associated with muscle physiology in 
the VA and PV at day 5 post-graft placement 
There were also a large number of transcripts down-regulated in both vein regions at day 
5. These genes were represented by the Morphogenesis, Organogenesis, and Development 
terms. GO terms related to muscle contractile phenotype (Muscle Development and Muscle 
Contraction) were commonly identified in the VA and PV among the enriched annotations (Table 
3.3). Exploration of genes represented by these terms revealed components of muscle 







Table 3.2 Over-represented GO terms for significantly up-regulated genes at 14 days 
post-graft placement in the VA (A) and PV (B). (A) At day 14 in the VA, GATHER analysis of the 
171 up-regulated transcripts representing 154 genes relative to the control EJV is shown. 
Osteo/chondrogenic pathway genes were enriched and were associated with developmental 
terms. (B) At day 14 in the PV, GATHER analyzed 75 up-regulated transcripts representing 70 











Table 3.3 Over-represented GO terms for significantly down-regulated genes at 5 days 
post-graft placement in the VA (A) and PV (B). (A) At day 5 in the VA, GATHER analyzed 342 
down-regulated transcripts representing 303 genes relative to the control EJV. Significant 
occurrences included GO terms related to organ morphogenesis, muscle physiology, and cell 
adhesion. (B) At day 5 in PV, 225 down-regulated transcripts representing 199 genes relative to 
the control EJV were analyzed. Genes related to organ morphogenesis and muscle contractile 
phenotype were significantly enriched.  
 





ITGB1BP2, MYOM1, MYH1, MYH11, SGCD), which were also associated with less refined 
developmental terms described above. Cell adhesion was another enriched GO class identified as 
down-regulated only in the VA, suggesting increased cell motility and plasticity changes during NH 
pathogenesis. At day 14 in the VA, a few GO terms associated with development were 
over-represented, as most of the down-regulated transcripts contributing to these terms at day 5 
were also significantly down-regulated at day 14 in the VA (Table 3.4). No significant annotations 
that satisfied our Bayes Factor cut-off were identified at day 14 in the PV. 
3.4.5 GO analysis of the genes that are commonly regulated 
between the VA and the PV  
Analysis of the genes that are significantly regulated in both the VA and the PV regions will 
provide insight into the early molecular and cellular events that broadly impact the damaged venous 
anastomosis as well as the adjacent vein regions. Up-regulated genes regulating cellular 
proliferation processes were enriched in these vein regions at day 5, although the relative 
enrichment of these genes was less significant compared to that in the VA region alone (Table 
3.5A). Down-regulated genes were represented by the Morphogenesis, Development, and 
Organogenesis terms at day 5 (Table 3.5B). Only up-regulated genes displayed a few 
over-represented GO terms associated with biological development (Table 3.5C) that satisfied the 











Table 3.4 Over-represented GO terms for significantly down-regulated genes at 14 days 
post-graft placement in the VA. At day 14 in the VA, GATHER analyzed 165 down-regulated 
transcripts representing 148 genes relative to the control EJV. No annotations that satisfied our 
Bayes Factor cut-off were identified at day 14 in the PV. 
 














Table 3.5 GO analysis of genes that are commonly regulated between the VA and the PV at 5 
(A and B) and 14 days (C) post-graft placement. At day 5 in the VA, GATHER analyzed 155 
up-regulated transcripts representing 142 genes (A) and 215 down-regulated transcripts 
representing 189 genes (B) relative to the control EJV. (C) At day 14 in PV, 62 up-regulated 
transcripts representing 57 genes relative to the control EJV were analyzed.  
 






3.4.6 Enriched biological properties and functions based on GO 
classifications in the VA 
We assigned each transcript that was either significantly up- or down-regulated in the VA 
to a biological property provided by the GATHER analysis (Figure 3.4). Since a given gene could 
be associated with multiple functional descriptors at different level of detail (depth of GO terms), 
we used the less-refined annotations at the same depth to categorize the transcripts to its key 
biological property. Functional classification indicated a marked increase in a cluster of 
up-regulated transcripts involved in Cell Proliferation at day 5, which did not persist into day 14. A 
cluster defined by Organogenesis that encompasses the osteo/chondrogenic terms in the 
up-regulated transcripts was more prominent at day 14. Among the down-regulated transcripts in 
the VA, the Metabolism, Cell Adhesion/motility, and Organogenesis clusters comprised substantial 
proportions of down-regulated genes at both time points. 
3.4.7 RT-PCR of expression of selected genes 
To validate our microarray results, we selected seven genes of interest and performed 
RT-PCR for the same RNA samples used for our microarray studies. The seven genes are the key 
components of the osteo/chondrogenic pathways that were significantly up-regulated in the VA 
(IBSP, SPP1, MMP9), muscle phenotype-specific genes significantly down-regulated in VA (CKM,  
ACTA2, CNN1), and a gene whose expression in the VA was not significantly altered compared to 
control EJV in the microarray study (ETS1). Microarray expression profiles of these genes in VA 





    
 
Figure 3.4 Enriched biological properties based on GO analyses in the VA. Each transcript 
analyzed by GATHER at 5 (A) and 14 (B) days post-graft placement was assigned to a GO term 
that describes its key biological properties. Pie charts show the proportion of up- (red circle) or 
down-regulated (green circle) genes involved in the indicated biological properties. A significant 
proportion of up-regulated transcripts at day 5 were classified into the Cell Proliferation category. 
At both time points, classification of down-regulated transcripts included substantial proportion of 





The expression of the housekeeping gene beta2 microglobulin (B2M) was used as a 
control gene for PCR. Figure 3.5 demonstrates that the PCR results generally agree well with the 
microarray studies in that IBSP, SPP1, and MMP9 were substantially up-regulated in both the VA 
and PV, although up-regulation of MMP9 at day 14 was not detected as significantly changed by 
microarray. There was a trend that CKM, ACTA2, and CNN1 were down-regulated, which was 
more prominent in the VA at 5 days. Expression of ETS1 was relatively stable at both time points.  
3.5 Discussion 
Incomplete understanding of the cellular and molecular mechanisms underlying the 
pathophysiology of venous NH formation in AVG motivated us to investigate the different genomic 
signatures of NH-prone and NH-resistant vein segments in a porcine model of AVG stenosis. This 
animal model recapitulates the AVG pathophysiology of humans, and venous NH formation is 
typically observed as early as a few days after the AVG placement and rapidly progresses over 
time, eventually resulting in stenosis and occlusion of the graft within several months (3, 5, 6). This 
accelerated development of NH in pigs enables us to efficiently study the early as well as the later 
changes in the development of NH. In our present study, examination of the VA and PV regions 
revealed different gene expression profiles in these vein regions that have different susceptibility 
to NH. We also demonstrated the differential transcription profiles in these regions at day 5 versus  
day 14 following AVG placement, a period characterized by early histological evidence of NH 
development (3).  





       
 
Figure 3.5 Quantitative RT-PCR measurement of seven select genes at 5 (A) and 14 (B) days 
post-graft placement. To confirm the microarray results of the expression of key genes in the VA 
and PV relative to the control EJV, RT-PCR was performed to analyze the gene expression levels 
for the same mRNA samples used for microarray experiments (N=4 for each data point). Error 





challenges with the incomplete and sometimes incorrect annotation of the genome. The first draft 
sequencing of the domestic pig (Sus scrofa) genome was accomplished by the International Swine 
Genome Sequencing Consortium (SGSC) in 2009, an effort led by the Wellcome Trust Sanger 
Institute. A revised and improved annotation was released at the end of 2012 (18, 19). Adding to 
this work, researchers have been collecting pig-expressed genes by a large-scale expressed 
sequence tag (EST) analysis and sequencing of entire cDNA clones using full-length-enriched 
cDNA libraries (20). Although an important advancement for livestock science and biomedical 
research, it will take time until the pig genome is as fully and accurately annotated as human or 
other model organisms such as mouse. As such, the current incomplete status of the pig genome 
annotation has limited our efforts to identify all of the porcine probes of interest in our microarray 
experiments, among the 43,803 probes represented in the Agilent porcine array.  
Analysis of the genomic signatures revealed that the most significant genes up-regulated 
in the VA and PV at day 5 following AVG placement have strong cell proliferation-associated 
annotations. These findings coincide with previous studies reporting the highly proliferative early 
stage of AVG NH development involving proliferation of smooth muscle cells (SMCs) and/or 
myofibroblasts (2, 3, 5-7, 21, 22). Our present results may also provide insight into which specific 
genes or pathways are implicated in the cell proliferation processes. Therapeutic strategies 
targeting cell proliferation at this early stage of NH development, therefore, may be more effective 
than aiming to inhibit proliferation at a later stage. Figure 3.6 proposes a time-course change in 
NH formation in the VA, and at least two distinct phases of NH development characterized by an 





   
 
Figure 3.6 Time-course progression of NH index in the VA and early and late pathologic 
events proposed to contribute to venous NH development. In anastomotic tissue sections 
obtained from our porcine model of AVG stenosis, NH index in VA increases over time (3). Our 
current genomic studies suggest that the early phase of NH formation may be characterized by 
enhanced cellularity driven by highly proliferative vascular cells. The later phase, however, may 
involve more prevailing cell/matrix remodeling, resulting in neointimal expansion. A list of key 
genes potentially contributing to each phase based on the microarray data is shown. Arrows 







interesting that the PV, a relatively NH-resistant vein region, also demonstrates enrichment of cell 
proliferation-associated genes at this time point, although such events appeared less prominent in 
this region compared to the VA.   
At day 14, we identified cellular events that have not been extensively reported in NH 
pathophysiology; Skeletal Development, Ossification, and Bone Remodeling. These events were 
also detected in the VA at day 5, although the relative importance of this gene set enrichment was 
diluted by up-regulation of many genes with cell proliferation-associated terms. This suggests that 
osteo/chondrogenic activities may take place early in NH initiation and is sustained for at least 2 
weeks. Tyson et al. demonstrated that vascular SMCs can exhibit osteo/chondrocytic phenotypes 
that correlated with the enhanced expression of mineralization-regulating proteins in calcified  
atherosclerotic plaques (23). The markers of calcification they tested included Sox9, Runx2 
(Cbfa1), and Ibsp, along with a few other osteo/chondrocyte-specific proteins. We were also able 
to identify a number of significantly up-regulated genes in the osteo/chondrogenic pathways from 
our gene set that are transcriptional targets of Sox9 and Runx2. These include SPP1, MMP9, 
MMP13, COL11A1, and SPARC, which were not directly tested by Tyson et al. The precise nature 
of vascular mineralization remains under investigation, although a few different hypotheses have 
attempted to explain its origin in response to pathogenic stimuli in arteries (24). Given the 
knowledge that calcification is actively suppressed in fully contractile, differentiated arterial SMCs 
 (23, 25, 26), our findings imply that venous NH in AVG may share fundamental similarities with 
osteo/chondrogenic vascular remodeling that occurs frequently in arterial diseases such as 
coronary artery disease. In addition, IBSP was shown to be implicated in angiogenesis as a 
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mediator of endothelial cell adhesion and chemotactic migration (27), and SPP1 may be involved 
in promoting vascular SMC proliferation (28). Whether these factors play a pivotal causal role in 
NH formation requires further investigation. 
As part of vascular structural remodeling in response to pathogenic cues, SMCs can adapt 
to perform various functions that are reflected in different SMC phenotypes; specifically contractile 
and synthetic phenotypes, with a range of intermediate phenotypes (29, 30). Previous studies 
have proposed that SMCs in NH lesions may dedifferentiate to more efficiently respond to injury 
and subsequent wound-healing activities, and along with changes in proliferation and migration 
potentials; the down-regulation of expression of SMC contractile genes would also be expected to 
occur in the dedifferentiated state (31-33). In fact, many down-regulated genes in our gene sets 
(e.g., ACTG2, DES, FHL1, MYOM1, MYH11, ITGB1BP2) are putative transcriptional targets of 
serum response factor (SRF), a master regulator of the SMC contractile apparatus (34). Our data 
demonstrating the down-regulation of muscle structural components and contractile apparatus 
support this proposal and point to a strong connection between SMC phenotypic conversion and 
NH development in AVG. It would be interesting to know whether inhibition of SMC phenotypic 
plasticity could attenuate the progression of NH lesions in AVG.  
We originally hypothesized that the gene expression profiles of the VA and PV will be 
different after AVG placement as the susceptibility to NH in the two distinct vein regions is different. 
There are a few factors that could influence this difference; the presence of surgical injuries and 
the graft material in the VA, and the more disturbed anastomotic hemodynamic environment. Our 
results suggest that the gene expression profiles did not clearly distinguish the VA from PV as a 
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number of cellular and molecular events appear to occur in common between the VA and PV. 
However, a larger number of genes were significantly regulated in the VA, and the relative 
enrichment of a series of genomic events was more prominent in the VA compared to the PV. A 
thorough understanding of these underlying molecular changes is expected to provide insight into 
the rational development of new therapeutic strategies that can improve the long-term 
performance of AVG. Our findings are also complementary to genomic and proteomic studies 
investigating hyperplasia-relevant pathways of NH formation in arterial diseases and other types of 





















Supplemental Figure 3.1 The spatial and temporal gene expression profile changes 







Supplemental Table 3.1 Differential expression of the key genes between the VA and PV at 
day 5 and day 14 post-graft placement. 
 







Supplemental Table 3.1 (continued). 
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GENE EXPRESSION IN PORCINE VENOUS ENDOTHELIAL  
CELLS IN RESPONSE TO SHEAR STRESS (IN VITRO  
 
LAMINAR SHEAR STRESS MODEL) 
 
4.1 Introduction 
The pathogenesis of neointimal hyperplasia (NH) associated with hemodialysis 
arteriovenous grafts (AVG) is incompletely understood to date. The end-products observed are 
increased smooth muscle cell (SMC) and endothelial cell  (EC) proliferation and migration, 
excessively deposited extracellular matrix (ECM) proteins, and inflammatory activities (1-3). 
Although multiple factors may contribute to NH development (discussed in section 1.3), the highly 
localized nature of NH forming predominantly at the graft-venous anastomosis (hereafter referred 
to as venous anastomosis) points toward pathophysiological hemodynamic stress as a key 
contributor (1, 2). Upon creation, AVG shunts arterial blood flow into the venous circulation, 
causing the vein at the anastomosis to stretch and dilate, which then generates locally aberrant 
flow patterns such as extremely high and/or low wall shear stress (WSS), WSS gradients, and 
reversed and/or oscillatory flow (1, 4-6). These drastic changes in the biomechanical environment 
may trigger the venous cells to physically and biochemically adapt to the new environment. 
Investigating the association between hemodynamic stress and NH formation (not only in venous
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AVG-induced NH, but more extensively studied in the context of arterial NH) has advanced our 
knowledge of the mechanosensitive properties of vascular cells. A number of early studies 
demonstrated that aberrantly high WSS can inhibit arterial SMC proliferation while low WSS 
induces proliferation by modulating the expression of certain growth factors (7-11). Low WSS was 
also shown to promote the entrapment of platelets and immune cells to NH-prone sites in the 
artery (1, 12). Enhanced tensile wall stress generally correlates with positive cell proliferation 
presumably via inducing the prosurvival cellular signaling pathways (1, 13-15). It is thought that 
cells actively participate in maintaining stress homeostasis by increasing the tissue mass to 
counteract elevated hemodynamic stress. Turbulent flow also contributed by stimulating the 
production of growth factors by SMCs, macrophages, and other immune cells within the NH 
lesions (16).  
Thus, to understand the potential underlying mechanisms of NH development in response 
to hemodynamic stimuli, studying the mechanisms by which vascular cells detect changes in 
biomechanical forces is important. In this regard, ECs have earned attention due to their unique 
location at the interface of the blood vessel tissue and the bloodstream. Normally, only ECs are 
directly exposed to luminal blood flow. Therefore, ECs are thought to be primarily responsible for 
transmitting biomechanical signals to the rest of the vessel wall. The mechanosensitive machinery 
in ECs consists of various cell junction molecules, cell surface receptors, effector proteins, and 
cytoskeletal components, which contribute to changes in EC structure, function, and their 
interaction with other vascular cell types like SMCs (17, 18). At the molecular level, such 
adaptation processes are reflected in gene and protein expression profiles that can be 
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differentially modulated under different biomechanical conditions.  
Numerous studies have reported the regulation of endothelial responses to fluid flow, fluid 
shear stress being the most intensively studied hemodynamic parameter among other types of 
hemodynamic stimuli. Research by Malek and Izumo showed that shear stress causes differential 
regulation of arterial EC products in that shear stress increases the expression of vasodilators 
(nitric oxide; NO) and reduces the production of vasoconstrictors such as PDGF-B and 
endothelin-1 (19). Chen et al. reported that long-term shear stress regulates the expression of 
genes related to inflammation and cell proliferation in aortic ECs, suggesting that such stimuli can 
promote vascular remodeling (20). Many others also reported that shear stress modulates the EC 
expression of a variety of genes encoding growth factors, chemoattractants, adhesion and 
coagulation molecules, and proto-oncogenes (21, 22). However, these studies were conducted 
using arterial ECs, whereas only limited information is available on whether venous ECs respond 
to shear stress in the same manner as arterial ECs. This is an important question for us, as NH 
formation occurs more frequently at the venous anastomosis in stenosed AVG. Abnormal changes 
in physiological shear stress are important in arterial diseases as the absence of or decreased 
shear stress may cause crucial pathologic situations for arteries (which are otherwise constantly 
exposed to high WSS). For example, atherosclerotic plaques have greater propensity to develop 
at arterial bifurcations and regions of high curvature where hemodynamics are complex and low or 
oscillatory WSS occurs (23, 24).  
The vein is normally exposed to much lower WSS (magnitude ranges from 1 to 5 
dyne/cm2) unless manipulated to encounter arterial circulation such as in vein grafts (24). 
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Therefore, it is likely that the venous ECs may display different biochemical properties from arterial 
ECs when exposed to nonphysiological shear stress. In our porcine model of AVG stenosis 
described in the previous chapters of this thesis, the venous anastomosis experiences sustained 
complex flow pattern changes characterized by extremely high and/or low WSS and WSS 
gradients compared to the juxta-anastomotic vein segments that are relatively resistant to NH 
formation (Figure 4.1). Effects of such pathophysiological WSS on venous EC physiology, 
especially at the molecular level, and their contribution to NH formation have not been defined 
clearly. 
Here we describe an in vitro model of laminar shear stress applied to a monolayer of 
primary venous ECs isolated from porcine external jugular veins (EJV). Using a porcine microarray, 
we examined the global gene expression profiles of isolated ECs continuously exposed to two 
different magnitudes of prolonged shear stress for 24 h: venous-level physiological (low) shear 
stress or arterial-level high shear stress, relative to gene expression profiles of ECs cultured under 
static conditions. We hypothesized that the differential gene expression between the static, low, 
and the high shear stress-exposed venous ECs indicates that pathologic WSS observed at the 
AVG venous anastomosis in vivo may contribute to the EC biochemical changes underlying NH 
development. Our findings could provide the first step in understanding the effects of 
hemodynamic stress on venous NH development associated with AVG stenosis.  
In addition, we employ the in vitro laminar shear stress model used in this study to 
investigate other physiological processes in bovine arterial ECs (BAEC) that are affected by shear 







   
 
Figure 4.1 Wall shear stress (WSS) profile changes in the venous anastomosis (VA) and in a 
vein segment slightly downstream of the venous anastomosis (PV; proximal vein) in a 
porcine AVG model. At day 5 following graft placement, unstable flow characterized by extremely 
high and/or low WSS is observed in both the VA and PV. Such WSS changes in the VA were 
sustained into day 14 whereas the magnitude of WSS change was decreased in PV at day 14. 
EJV indicates a control vein from the unoperated contralateral side of each animal. The average 








sensitizes the NO response in BAECs, resulting in greater eNOS activation and enhanced 
production of NO. Increased local temperature in human skeletal muscle feed arteries have been 
shown to reduce alpha1-adrenergic receptor-mediated vasoconstriction; however, the underlying 
mechanisms have not been elucidated. Ives et al. hypothesized that the thermal effects could be 
due to the vasodilatory actions of nitric oxide (NO) produced by the endothelium through shear 
stress stimulation of endothelial NO synthase (eNOS) (25). In this chapter, the laminar shear 
stress experiments used to evaluate this hypothesis are described, and results and discussions of 
the results are referred to the published work by Ives et al. (25).     
4.2 Materials and Methods 
4.2.1   Materials 
Cell culture reagents including EBM-2 media and growth supplements for porcine venous 
ECs were purchased from Lonza (Walkersville, MD). BAECs and Dulbecco’s Modified Eagle 
Medium (DMEM) were purchased from Life Technologies (Grand Island, NY). Collagenase A was 
obtained from Roche Applied Science (Indianapolis, IN). Antibodies directed against von 
Willebrand Factor (vWF) were purchased from DAKO Pharmaceuticals (Carpinteria, CA), and 
smooth muscle alpha-actin antibodies were from Sigma (St. Louis, MO). Porcine anti-CD31 
antibodies were obtained from R&D Systems (Minneapolis, MN). Secondary antibodies used for 
fluorescence microscopy were obtained from Life Technologies. Glass microslides and silicone 
sheeting for in vitro flow experiments were purchased from Corning (Corning, NY) and Specialty 
Manufacturing Inc. (Saginaw, MI), respectively. Fibronectin solution from bovine plasma was 
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purchased from Sigma. All reagents and materials for RNA isolation and microarray experiments 
are described in in Chapter 3. 
4.2.2 Isolation of porcine venous ECs and cell culture 
Animal procedures were performed aseptically in accordance with a protocol that was 
approved by the Institutional Animal Care and Use Committees (IACUCs) at the Veterans Affairs 
Salt Lake City Health Care System and the University of Utah. Female Yorkshire cross domestic 
pigs (Sigma Livestock, Salt Lake City, UT) weighing approximately 30 to 35 kg were used to collect 
venous ECs from the EJV. Preparation of animals including anesthesia is described in detail in 
Chapter 2.  
Primary porcine venous ECs were collected from fresh, unoperated EJVs by collagenase 
A tissue digestion. Briefly, an EJV segment of about 5 to 7 cm was ligated at both ends, and warm 
collagenase A solution (1 mg/ml concentration diluted in serum-free cell culture media) was 
injected directly into the lumen of the ligated EJV segment. After incubation for 5 min, followed by 
rigorous massaging of the vessel wall using sterile techniques, contents were emptied into a 
container filled with fetal calf serum (FCS) to inactivate the enzyme reaction. Cells were harvested 
by gentle centrifugation and cultured in flasks in EBM-2 media in a humidified 37 C incubator with 
5% CO2 and 95% ambient air. EC cultures were expanded to produce batches of passage number 
5 to 6 cells. Cells isolated this way produced a homogenous EC population devoid of other cell 
types, such as SMCs, at our desired passage number when determined by immunostaining. 
Before each flow experiment, we confirmed the endothelial nature of these cells by positive vWF 
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and CD31, and negative smooth muscle -actin immunostaining (Figure 4.2). Briefly, sampled 
cells from each EC batch were seeded onto 2-well chamber slides at a density of 1x105 cells/well 
and grown overnight in a tissue culture incubator. Cells were then fixed in 2% paraformaldehyde, 
followed by permeabilization in 0.5% Triton X-100 solution. Cells were incubated overnight at 4 C 
with primary antibodies specific for the respective proteins. Proteins were visualized by 
immunofluorescence. Three different animals were used to collect ECs from EJVs, and cell 
cultures from each animal were maintained separately. For all flow experiments, EC cultures at 
passage 5 to 6 were used.  
Commercially purchased BAECs Life Technologies (Grand Island, NY) were cultured in 
flasks in DMEM supplemented with 10% FCS. Cultures were maintained in a humidified 37 °C 
incubator with 5% CO2 and 95% ambient air. All experiments were conducted with cultures at 
passage 3 to 6. 
4.2.3 Preparation of matrix-coated microslides 
Glass microslides (28.5 cm2, 1 mm thickness) and silicone sheeting with two different 
thicknesses (0.025 or 0.05 cm) cut to expose the flow channel were cleansed and sterilized before 
use. The flow channel has a length of 5.5 cm, a width of 2.5 cm, and a height of either 0.025 cm or 
0.05 cm, for generation of high or low shear stress, respectively. This channel was created 
between the microslide and the parallel-plate flow chamber, separated by the silicone gasket. 
Bovine plasma fibronectin (1 mg/ml), diluted in phosphate-buffered saline (PBS), was coated as a 











Figure 4.2 Immunostaining of isolated porcine venous ECs with vWF, CD31, and smooth 
muscle -actin at passage number 5. Porcine venous ECs were isolated from EJV using 
collagenase A tissue digestion and EC cultures were expanded. At passage number 5, sampled 
cells were immunostained for either vWF (cytosolic, appearing green in panel a), CD31 
(membranous, appearing red in panel b) or smooth muscle -actin (blue staining only in panel c 
denotes nuclei and negative staining for -actin) to confirm their endothelial nature and to examine 
any SMC contamination. ECs were positive for vWF and CD31, and negative for smooth muscle 









was incubated on slides for 2 h at room temperature to allow matrix adsorption. Porcine EC 
cultures at passage 5 to 6 or BAEC cultures at passage 3 to 6 were seeded onto these 
fibronectin-coated surfaces at a density of 1x105 cells/slide and were grown to approximately 80 to 
90% confluence before each shear stress experiment.  
4.2.4 In vitro laminar shear stress experiments 
The in vitro unidirectional laminar shear stress model was described similarly by Shiu et al. 
and Albuquerque et al., with modifications to enable application of a wide range of shear stress 
values (26, 27). The system consists of an upper and a lower reservoir from which the oxygenated 
culture media continuously recirculates through the flow channel to shear cells at a defined 
volumetric flow rate calculated to generate specific shear stress values. Volumetric flow rate (Q) 
was measured manually through a flow meter positioned immediately downstream of the flow 
chamber. Sterile techniques were maintained in the 37 C constant-temperature hood throughout 
the experiment. Shear stress () was calculated using the following equation:  = (6Q)/(wh2), 
where  is the viscosity of the culture media containing serum ( = 0.01 Poise), Q is the volumetric 
flow rate (determined at the time of each experiment), w is the width, and h is the height of the flow 
channel. We conducted 3 sets of independent shear stress experiments with the venous ECs 
collected from three different animals (N=3 for each group). In each set, cells derived from the 
same animal were either exposed to continuous low shear stress (2 to 5 dyne/cm2) or high shear 
stress (35 to 40 dyne/cm2) for 24 h, with each condition having a technical replicate. The flow 
system was maintained at 37 C and culture media was supplied with 5% CO2 in balanced air. 
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Control ECs with the same passage number as with the sheared cells were seeded onto 
fibronectin-coated microslides in an identical manner and were cultured under a static, 
undisturbed condition for 24 h in a tissue culture incubator.  
The same preparation procedures were conducted for BAECs except that these cells 
were exposed to only high shear stress (15 to 20 dyne/cm2) for 1 h. This is within the physiological 
range of major human arteries and has been documented to activate EC signal transduction (21). 
The flow system was kept at either 37 C or 39 C in a constant-temperature hood. Control ECs 
with the same passage number as with the sheared cells were seeded onto fibronectin-coated 
surfaces in an identical manner and were cultured under a static flow, undisturbed condition at 
either 37 C or 39 C for 1 h in a tissue culture incubator. Upon completion of the flow experiments, 
cell lysates were collected in ice-cold lysis buffer containing detergent, and standard Western 
blotting procedures were performed (25).        
4.2.5 RNA extraction and microarray hybridization 
After 24 h of exposure of porcine venous ECs to laminar shear stress, cells were 
immediately washed with warm PBS. Cells were then directly lysed in 1 ml of QIAzol Lysis 
Reagent (Qiagen) on the microslides and lysates were collected with a rubber cell scrapper. A  
separate set of cells were subjected to phase contrast microscopy for morphological examination 
after exposure to shear stress, and these cells were not used for RNA extraction (Figure 4.3). 
Extraction of total mRNA, RNA labeling, and microarray hybridization on Agilent porcine 44K (v1) 








   
 
Figure 4.3 Morphological changes of cultured porcine venous ECs exposed to low or high 
laminar shear stress for 24 h. After exposure to laminar shear stress for 24 h, ECs cultured on 
fibronectin-coated microslides were washed in warm PBS and their morphological changes in 
response to shear stress were assessed using phase contrast microscopy. Compared to ECs 
grown under static condition that remained randomly oriented (a), ECs aligned in the direction of 
flow in both low (b) and high (c) shear stress-exposed cells. Flow direction was from right to left as 









extracted this way displayed RNA Integrity Number (RIN) greater than 9 in all samples.  
4.2.6 Bioinformatics analyses of gene expression profiles 
Data normalization and adjustment of batch effects were conducted as described in 
Chapter 3, except that microarrays were processed in three batches over the course of several 
months. Following normalization and batch-adjustment, hierarchical clustering revealed that 
samples were clustered by shear stress conditions with low and high shear stress-exposed 
samples being similar. Batch-adjusted data were uploaded into GeneSifter® Analysis Edition v3.7 
(http://www.genesifter.net, Geospiza, Seattle, WA) for statistical analysis. 
Transcripts with mean fold-changes of ≥ 4.0 and ANOVA p < 0.05 (Benjamini and 
Hochberg correction) in either the low or high shear stress groups (or both) compared to their 
corresponding transcripts from common static control were first filtered. After filtering, there were 
414 transcripts that satisfied our threshold, which included un-annotated transcripts with no 
accession numbers. These transcripts were excluded for further genomic analyses. For 
uncharacterized probes with a primary accession number, we used nucleotide basic local 
alignment search tool (BLAST) to manually determine similar sequences in other species using 
sequence matches above a specified cut-off threshold (≥ 50% matching query-subject coverage 
and E-value ≤ 10-4). In most cases, an annotated “hit” with the highest total score that fulfilled our 
specified threshold criteria was selected as the genes to be used for further analysis. GATHER 
analysis was performed as described in Chapter 3. Annotated transcripts significantly altered in  
each of the two shear stress conditions were separately subjected to GATHER analysis. Also, up- 
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or down-regulated transcripts were separately analyzed. 
4.2.7 Quantitative reverse transcriptase-PCR 
The same mRNA samples used for microarray studies were subjected to Taqman 
quantitative RT-PCR. Details of the experiment are described in Chapter 3. We assessed the 
expression of five key genes selected from the microarray studies (ANGPT2, F2, CIDEC, KLF4, 
and SELL). PCR amplification efficiencies were similar for all genes tested. Relative gene 
expression was normalized to the expression of the housekeeping gene, beta-2 microglobulin 
(B2M), and the comparative CT method was used to quantify the fold differences in gene 
expression.  
4.3 Results 
4.3.1 Morphology of venous ECs in response to shear stress 
We examined the morphology of porcine venous ECs exposed to either low (2 to 5 
dyne/cm2) or high (35 to 40 dyne/cm2) unidirectional laminar shear stress for 24 h. The overall 
monolayer integrity of the cells and their shapes after the long exposure time in vitro were 
assessed using phase contrast microscopy. Elongation and alignment of cells in the direction of 
flow was observed with shear stress (Figure 4.3 panels b and c), whereas the cells cultured under 
static condition remained randomly oriented (Figure 4.3 panel a). Such observations are 
consistent with EC cytoskeletal alignment under flow reported in a number of previous studies 
(28-30). This demonstrates that the level of shear stress, especially the high shear stress, applied 
to monolayer ECs grown on fibronectin-coated microslides, did not cause damage to the cells nor 
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detachment of cells from the microslides during the 24 h experiment, and was able to induce 
morphological changes. 
4.3.2 Global gene expression changes in low and high shear 
stress-exposed venous ECs 
We compared the global genomic changes of low and high shear stress-exposed venous 
ECs relative to the common control ECs grown under static conditions for the same period of time. 
DNA microarray analysis identified hundreds of transcripts that were significantly regulated in 
either low shear or high shear environments or both. A threshold (mean fold-changes of ≥ 4.0 and 
ANOVA p < 0.05) was applied to filter transcripts that are significantly regulated in response to 
shear stress. As discussed in Chapter 3, this criterion takes the magnitude of variations in normal 
gene expression variations reported in the literature into consideration and allows us to efficiently 
explore the massive microarray data set for identifying genes with the most relevant biological 
significance. Analyses of both low and high shear stress-modulated genes showed that 414 
transcripts met our threshold and were significantly different between the sheared and static  
EC cultures. Figure 4.4 illustrates the global gene expression profiles of the filtered transcripts 
presented as a microarray heat map (each group N = 3). Clustering of samples showed that the 
two shear stress-exposed groups were more similar to each other than to the static control group. 
Due to incomplete annotation of many transcripts on the array, un-annotated transcripts with no 
accession numbers were excluded from further data analyses, leaving 223 filtered transcripts.  
In Figure 4.5, Venn diagrams of the 223 filtered transcripts indicate that a substantial 
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Figure 4.4 Gene expression profile changes of low or high shear stress-exposed venous 
ECs. GeneSifter identified 414 transcripts that met our selection threshold from three independent 
microarray experiments. Sample clustering indicates that the two shear stress-exposed groups 
were similar to each other than to the static control group (each group N=3). The color-coded scale 







               
 
Figure 4.5 Venn diagrams indicating the degree of overlap between low and high shear 
stress-exposed ECs. A substantial number of the 223 filtered transcripts overlap between the 
low- and high-shear stress groups. The numbers of up- (red) or down-regulated (green) transcripts 
are shown. Greater number of transcripts was differentially regulated in high shear stress-exposed 







number of regulated transcripts that satisfied our threshold criteria were shared between the two 
different shear stress groups, and more transcripts were significantly regulated in the high shear 
stress group compared to the low shear stress group. These findings suggest that even a 
physiological level of low shear stress was capable of inducing EC genomic changes similar to 
those observed with much higher shear stress level. 
4.3.3 Gene enrichment of significantly up- or down-regulated 
transcripts in response to low or high shear stress 
A total of 112 and 140 transcripts for low and high shear stress-exposed ECs, respectively, 
were subjected to GATHER’s Gene Ontology (GO) analysis. Analysis of up-regulated genes in 
each shear stress group revealed that the most significant (Bayes factor ≥ 6) biological process 
enriched among low shear stress-regulated genes was strongly related to STAT protein nuclear 
translocation and cell communication (Table 4.1A). The two genes that were associated with both 
annotations were F2 and F2R, which are thrombin and thrombin receptor, respectively. Significant 
up-regulation of dopa decarboxylase (DDC) in the high shear stress group was associated with  
terms related to biosynthesis of dopamine (Table 4.1B). However, all of the significantly identified 
terms pertaining to dopamine biosynthesis were associated with this one gene (DDC) only, 
suggesting that there was no meaningful enrichment of dopamine biosynthesis or other gene sets 
among the high shear stress-modulated genes that were up-regulated. 
When down-regulated genes were examined for each shear stress group, annotations 







Table 4.1 Over-represented Gene Ontology (GO) terms for significantly up-regulated genes 
in the ECs exposed to low (A) or high (B) shear stress for 24 h. (A) GATHER analysis of the 
72 up-regulated transcripts representing 70 genes in ECs exposed to low shear stress relative to 
the static control ECs is shown. Only two annotations were identified with a meaningful Bayes 
Factor (≥ 6). (B) GATHER analyzed 89 up-regulated transcripts representing 86 genes in ECs 
exposed to high shear stress relative to the static control. Although terms related to dopamine 
biosynthesis were identified as most significant, only one gene (DDC) contributed to these terms. 
     








(Table 4.2A and B). Significantly regulated genes that contributed to these terms included 
cytokines such as CCRL1, CXCL2, CXCL5, CXCL10, CXCL14, SPP1, and RPS6KA5. Microarray 
expression profiles of these genes are shown in Table 4.3. 
4.3.4 RT-PCR of expression of selected genes 
To validate our microarray results, we selected five genes (ANGPT2, CIDEC, F2, KLF4, 
and SELL) whose expressions were significant and differentially regulated between the low and 
high shear stress (Table 4.3) and performed RT-PCR for the same RNA samples used for our 
microarray studies. Studies conducted by others in vascular ECs have shown that ANGPT2 and 
KLF4 are regulated by laminar shear stress in the same direction as we observed here (31-33). 
CIDEC, F2, and SELL perform important cellular functions such as focal adhesion (34, 35), cell 
alignment, and migration and thrombosis, but modulation of these genes by shear stress in ECs 
has not been reported in the literature. Microarray expression profiles of these genes are shown in 
Table 4.3. The expression of the housekeeping gene beta2 microglobulin (B2M) was used as a 
control gene for PCR. Figure 4.6 demonstrates that the PCR results generally agree well with the 
microarray studies except that F2 expression change was similar between the two shear stress 
groups when examined by PCR. 
4.4 Discussion 
Shear stress is a key hemodynamic force that plays a pivotal role in regulating the 
physiological processes in cells of the blood vessel wall. It is widely appreciated that 





Table 4.2 Over-represented GO terms for significantly down-regulated genes in the ECs 
exposed to low (A) or high (B) shear stress for 24 h. (A) GATHER analysis of the 40 
down-regulated transcripts representing 37 genes in ECs exposed to low shear stress relative to 
the static control ECs is shown. (B) GATHER analyzed 51 down-regulated transcripts representing 
47 genes in ECs exposed to high shear stress relative to the static control. Under both conditions, 
genes associated with response to stress or stimuli were significantly enriched. 
 








Table 4.3 Differential gene expression in porcine venous ECs in response to 24-h low or 
high shear stress. 
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Table 4.3 (continued). 
 









             
Figure 4.6 Quantitative RT-PCR measurements of five select genes that are differentially 
regulated between ECs exposed to low and high shear stress from microarray studies. To 
confirm the microarray results, RT-PCR was performed to analyze the gene expression levels for 
the same mRNA samples used for microarray experiments (N=3 for each data point). Error bars 










the AVG venous anastomosis, can induce a variety of pathogenic events resulting in structural and 
functional changes in affected cells. In the present study, we investigated the effects of shear 
stress on gene expression profiles in cultured porcine venous ECs to elucidate genes and/or 
cellular pathways that may be important mediators of venous NH development associated with 
AVG stenosis. The in vitro experimental flow system we adopted here does not perfectly 
recapitulate the in vivo conditions in the venous anastomosis. However, this model addresses 
several important factors because biological effects of specific hemodynamic parameters (e.g., 
shear stress) on specific cell types (e.g., ECs or SMCs) can be studied, which cannot be 
separated from other pathogenic factors in complex in vivo flow environments. This provides us 
with information on the underlying cellular and molecular events induced by pathophysiological 
hemodynamics that may potentially be implicated in NH development. 
Using this system, porcine venous ECs were exposed to either physiological venous (low) 
shear stress or arterial (high) shear stress continuously for 24 h, and their gene expression 
changes relative to statically cultured ECs were assessed. Although we adopted the static value 
as a reference control to elucidate shear stress-dependent changes, it is important to note that 
venous ECs are physiologically exposed to low shear stress, and the absence of shear stress may 
be considered nonphysiological. Previous studies demonstrated that sudden application of shear 
stress to statically cultured ECs can induce drastic changes in the initial genomic profiles. Many of 
these immediately responsive genes, however, are thought to be transient and return to baseline 
level after sustained exposure to shear stress, for example, for 24 h (20). Since prolonged 
shearing of ECs may be more physiologically relevant to the flow conditions occurring in vivo than 
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short-term exposure, we examined the gene expression profiles in response to sustained shear 
stress.  
Gene enrichment analysis of significantly regulated genes that satisfied our threshold 
criteria revealed that a few enrichment terms were associated with up- or down-regulated gene 
sets from each shear stress group. Among the up-regulated genes in the low shear stress group, 
F2 and F2R contributed to two terms identified as significant, STAT protein nuclear translocation 
and Cell communication. These genes were also significantly up-regulated in the high shear stress 
group. It is also interesting to note, however, that expression of F2R was down-regulated in 
response to 24 h arterial shear stress in human umbilical vein ECs (HUVEC) and in microvascular 
ECs in a study conducted by Nguyen et al. (36). Although ECs of different origins can respond to 
shear stress differentially, the discrepancy between our study and theirs is not clear. Analysis of 
significantly down-regulated gene sets in both shear stress groups showed that cytokines related 
to stress/stimuli response were enriched. Shear stress-mediated modulation of cytokines and 
chemokines has been previously studied by others (37), although modulation of the specific 
cytokines that we identified in this current study has not been reported before (CCRL1, CXCL2, 
CXCL5, CXCL10, CXCL14, and SPP1). 
Increasing evidence shows that there is a spectrum of shear stress-modulated genes that 
are common between a number of different studies of similar or different vascular cell types. In this 
context, many genes that were significantly regulated in response to shear stress from our venous 
EC microarray studies have been shown to be regulated in arterial and other ECs. For example, 
endothelial Krüppel-like factor (KLF) genes are shear stress-responsive transcription factors that 
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regulate cellular differentiation and tissue development (38), and previous studies showed that a 
few members of the KLF genes were significantly induced by laminar shear stress in arterial ECs 
(32, 39, 40). In our microarray study, we identified KLF4 to be differentially up-regulated under high 
shear stress conditions. In addition, angiopoietin-2 (ANGPT2), a critical regulator of vascular 
stabilization and maturation, was shown to be down-regulated by high flow in HUVECs in vitro by 
others, an observation in agreement with ours (41).  
We had hypothesized that the gene expression profiles between low and high shear 
stress-exposed venous ECs would be different as pathologic shear stress can induce a variety of 
cellular processes which may contribute to venous NH development in AVGs. Results from our 
current study revealed that many shear stress-responsive genes were differentially regulated 
between the two groups, and analysis of enriched genes and/or pathways in each group provided 
us with knowledge of the underlying biological events (Table 4.3). Further investigation on how 
shear stress-dependent genes act together to alter the endothelial physiology in 
hemodynamically-adapted venous ECs is necessary. Gene expression data of this in vitro study 
can also be compared to the whole porcine AVG tissue microarray results discussed in Chapter 3, 
to determine the shear stress-dependent endothelial genes and/or pathways that are significantly 
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 SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
In the United States, more than 20% of all hospitalizations in hemodialysis population and 
up to 50% of the first year hemodialysis costs are associated with vascular access complications 
(1). The complexity of the pathophysiology underlying AVG and AVF vascular access failures has 
largely obstructed our efforts to resolve this important clinical problem. Focusing on the 
pathophysiology of the AVG stenosis, the major goal of our study is to propose that improved 
understanding of the complex cellular and molecular mechanisms contributing to early NH 
development is essential in devising future therapeutic strategies aimed at preventing and/or 
treating AVG stenosis and failure.  
Among the multiple pathogenic factors contributing to the venous NH pathogenesis, 
pathophysiological hemodynamics is thought to play an important role in localized NH 
development (2, 3). Based on this notion, we employed an ex vivo perfused vein culture model to 
investigate the therapeutic potential of an antineoplastic agent, sunitinib, in inhibiting venous NH 
formation under aberrant hemodynamic conditions. In in vitro experiments, sunitinib inhibited 
growth factor-stimulated proliferation and migration of human vascular cells, and the intracellular 
signaling components implicated in its inhibitory mechanism were revealed. Sunitinib then 
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significantly attenuated the formation of venous NH lesions in the vein culture model that 
reproduces the pathogenic WSS observed in vivo. We also highlighted the utility of this ex vivo 
culture model for evaluating potential NH-preventive agents. Our findings have led us to suggest 
that sunitinib may be an effective pharmacological inhibitor of NH.  
We employed a porcine global gene expression microarray analysis to investigate the 
genomic changes underlying venous NH development in a porcine AVG stenosis model. We 
demonstrated that a number of genomic events were regulated in common between the NH-prone 
VA and the NH-resistant PV regions. However, a larger number of genes were significantly 
regulated in the VA, and the relative enrichment of a series of genomic events was more prominent 
in the VA compared to the PV. Among these genomic events, we identified the osteo/chondrogenic 
processes to be up-regulated, which has not been extensively reported in NH pathophysiology, 
and genes related to muscle contractile phenotype to be down-regulated in the VA. 
We next explored the genomic responses of porcine venous ECs exposed to physiological 
and pathophysiological shear stress in an in vitro laminar flow system. We found that many shear 
stress-responsive genes were differentially regulated between ECs exposed to prolonged low and 
high shear stress; however, how shear stress-dependent genes act together to alter the 
endothelial physiology in the context of venous NH requires further investigation. 





5.2 Future Directions 
5.2.1   Chapter 2 
Our findings encourage future investigations into whether sunitinib demonstrates 
NH-preventive efficacy in vivo, such as in a porcine AVG stenosis model. In order to locally 
administer sunitinib to the desired site of action (i.e., venous anastomosis), an appropriate means 
of drug delivery should be devised. Our laboratory recently developed a polymer-based 
perivascular wrap system for controlled and directed delivery of sunitinib as a model drug. In 
porcine in vivo release studies using this wrap, sustained release of sunitinib at efficacious levels 
around the wrapped external jugular vein was accomplished for at least 4 weeks (4). In vivo 
efficacy studies of sunitinib with positive results will complement our current in vitro and ex vivo 
studies, and therefore will corroborate the therapeutic potential of sunitinib as an NH-preventive 
agent for the treatment of hemodialysis AVG stenosis. 
5.2.2   Chapter 3 
The global gene expression profiles of the NH-susceptible vein region in our porcine AVG 
model suggested that a variety of genomic events may be implicated in venous NH development. 
Future studies can be directed towards exploring each of these altered processes and determining 
their potential role in NH development. Especially the osteo/chondrogenic pathways that were 
significantly altered in our microarray results may be of particular interest. Although a few 
components in these pathways have been shown to be implicated in cellular events strongly 
associated with hyperplasia formation (5, 6), much more research needs to be done on 
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characterizing vascular calcification and its potential involvement in NH formation in the vein.  
5.2.3   Chapter 4 
Since NH development occurs predominantly at the venous anastomosis, it is important to 
understand how vascular cells of the vein respond to putative pathogenic factors that are 
responsible for NH formation. Exploring the gene expression changes in response to abnormal 
shear stress in porcine venous ECs provided us with some knowledge of the cellular and 
molecular processes that may be involved in NH development. However, ECs are one of the three 
major cell types that constitute the blood vessel wall; thus, it would also be interesting to examine 
the shear stress-induced genomic changes in SMCs, fibroblasts as well as in co-culture models of 
two or more of the above cell types. Future work may also consider comparing genomic profiles of 
in vivo NH lesions and vascular cells subjected to in vitro flow studies to determine any shear 
stress-dependent events that may be hyperplasia-relevant.  
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EX VIVO PERFUSED ORGAN CULTURE SYSTEM AND  
FLOW EXPERIMENTS TO STUDY THE EFFECTS OF  
 
SUNITINIB ON VENOUS NH FORMATION 
 
A.1 Introduction 
The perfusion of blood vessel segments ex vivo offers significant advantages over static 
vessel culture models by allowing for exposure to dynamic and more physiologically relevant 
culture environment. Therefore, the ex vivo perfusion systems, such as the ex vivo system 
described in Chapter 2, have been a useful tool in the investigation of short-term and/or long-term 
physiological or pathophysiological effects on explanted vessel segments. In Chapter 2, a laminar 
flow ex vivo perfusion system was employed to evaluate the antihyperplastic properties of sunitinib 
on flow-induced venous NH formation. A detailed description of the construction of this perfusion 
system, including all materials, and the procedures of the flow experiments are provided in this 
Appendix. Application of this unique perfusion system may include studies of other common 
venous and/or arterial pathophysiology that require more physiologically-relevant models than 
monolayer cell cultures. 
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A.2 Materials and Methods 
A.2.1 Materials 
Tissue culture-grade silicone (Masterflex PharMed BPT®) and Tygon tubing, tubing 
connectors, fittings, and all other accessories were purchased from Cole-Parmer (Vernon Hills, IL). 
Tubing with various inside diameters were used which approximately ranged from 0.5 mm to 10 
mm. The peristaltic pump and all pump accessories were also obtained from Cole-Parmer. All 
glassware was custom-made in the research glassblowing shop and the vessel chamber in the 
mechanical shop from the Department of Chemistry at the University of Utah. 5% CO2 
compressed balance air was purchased from the General Stores and Receiving at the University 
of Utah. All tissue culture reagents were purchased as described in Chapter 2. 
A.2.2 Methods 
A.2.2.1 Sterilization. Sterilization of all parts and accessories including the vessel 
chamber before each and every experiment is important as bacterial contamination of explanted 
tissues can produce unreliable experimental results. If bacterial contamination is present during 
explant and/or during placement in the vessel chamber, obvious bacterial growth may be observed 
within 24 h (e.g., media color change and odor), and tissues are immediately discarded. 
 All glassware (the two culture media reservoirs and a water chamber), tubing, and tubing 
accessories (connectors, fittings, adapters, and flow valve) were washed and autoclaved under 
dry cycle for at least 30 min prior to each experiment. The vessel chamber was disassembled and 
all metal accessories were also washed and autoclaved. After connecting the glassware and 
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tubing, the entire flow system was placed in a tissue culture hood and inner surface was washed 
twice with 70% ethanol using a peristaltic pump, followed by rinsing with sterile distilled water for at 
least three times to completely remove ethanol. The flow system was allowed to dry in clean air 
overnight in the culture hood.  
A.2.2.2 Vessel explant. On the day of perfusion experiment, the vessel chamber tub and 
cover was soaked in 70% ethanol for at least 10 min prior to placement of vein segments and then 
completely dried in clean air. The flow system was rinsed once more with DMEM without serum in 
order to remove residual water inside the tubing. Using sterile techniques in the surgery suite, vein 
segments (3 to 5 cm in length) freshly harvested from pig internal jugular veins were fixed onto the 
metal adapters and collected in DMEM containing 30% serum and two time’s concentrated 
antibiotics (gentamicin and amphotericin B). Upon transfer to the tissue culture room, vein 
segments were kept in the same media and placed in a tissue culture incubator until ready for 
placement. This time period usually did not exceed 2 h from beginning of vessel explant and tissues 
were managed as quickly as possible.  
A.2.2.3 Flow system assembly. In the tissue culture hood, the vein segment was placed 
in the vessel chamber at its in vivo length (using the grid inscribed on the bottom of the vessel 
chamber tub) and the metal adapters were connected to the tubing using sterile gloves (Figure A.1). 
Before adding media that fills the chamber tub, the vein was checked for any leakage by flowing 
media through the vessel for 5 to 10 min. Any vessels that showed leakage due to incomplete 
ligation of small branches or holes were discarded. Finally, the entire flow system was transferred 





            
            
               
 
 
Figure A.1 The ex vivo perfused blood vessel organ culture model. (A) The flow system 
consists of a peristaltic pump, two reservoirs that hold the culture media and a blood vessel 
chamber. The system is aerated with moist 5% CO2 balance air and the temperature is controlled 
at constant 37 C. (B) Explanted vein segments were fixed onto the metal tubes at their in vivo 





tubing that flows sterile 5% CO2 balance air (air passes a syringe filter to maintain sterility), and the 
flow hood was set to 37 C. Volumetric flow rate was measured manually through a flow valve 
positioned immediately downstream of the vessel chamber. A detailed description of how WSS 
was calculated is stated in Chapter 2. 
A.2.2.4 Flow experiments. Fresh media was supplied every 2 to 3 days and the vein 
segments were cultured for 12 consecutive days with media flowing continuously. When changing 
old media, the entire system was transferred into the tissue culture hood to prevent contamination 
due to exposure of vessels to open air. Sunitinib was added to the media on the second day of 
culture and throughout 12 days. Bacterial contamination was determined by microscopic visual 
examination of the culture media. If strong odor and obvious color change in media developed, 
vessels were immediately discarded. In some cases, bacterial contamination could only be 
observed microscopically without changes in media color and odor. These vessels were closely 
monitored and fresh media was supplied every 1 to 2 days, and vessels were utilized for data if still 
no change in media color occurs. At the end of experiments, vessels were fixed in 10% neutral 
buffered formalin for 24 to 48 h as described in Chapter 2, without removing from the vessel 
chamber. After each and every experiment, the flow system was disassembled, washed with mild 
detergent, and completely dried in air. 
A.3 Conclusion 
The ex vivo perfusion system we employed is a unique tissue culture model of venous NH 
that can be used to rapidly screen potential pharmacological inhibitors of NH. Careful preparation 
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of the flow experiments is important to prevent bacterial contamination of the explanted tissues. 
The above procedures, if properly followed, have proven to reduce contamination problems 
associated with mishandling of the tissues and the flow system.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
